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ABSTRACT 
A large number of pharmaceutically important drugs are poorly soluble in water. This 
study focuses on the 'smart' molecule that can enhance the solubility and hence increase 
the bioavailability of these drugs. This molecule is a cyclodextrin and is known to form 
inclusion compounds with various drug molecules. 
The preparation of P-cyclodextrin CP-CD), y-cyclodextrin (y-CD), heptakis(2,6-di-O-
J, 
methyl)-p-cyclodextrin (Dimeb) and heptakis(:J>·tri-0-methyl)-P-cyclodextrin (Trimeb) 
3, 
complexes with clofibric acid as well as the heptakis(2j·tri-O-methyl)-p-cyclodextrin 
(Trimeb) complex with clofibrate is reported. The complexes were characterised by 
thermogravimetric analysis (TG), differential scanning calorimetry (DSC), ultraviolet 
spectrophotometry (UV), infrared spectroscopy (IR), X-ray powder diffraction (XRD) 
and single crystal X-ray analysis. 
Infrared spectroscopy for the four inclusion complexes of clofibric acid showed a 
significant shift of the C=O stretching frequency in the complexed drug relative to the 
uncomplexed drug. 
The crystal structures of the complexes, except that of the Dimeb complex with clofibric 
acid, were solved. The guest molecules in the P- and y-CD complexes were found to be 
disordered, preventing detailed interpretation of the mode of inclusion. The guest 
molecules in the two Trimeb complexes were resolved and the modes of inclusion were 
revealed. The aliphatic chains of the guests were found to be inserted in the cavity, while 
the chlorophenyl rings protrude from the secondary side of the Trimeb molecule. Kinetics 
of dehydration studies for P- and y-CD complexes of clofibric acid, as well as for their 
iv 
corresponding hosts were carried out. Attempts were made to correlate the kinetic 
behaviour with the crystal structures of these compounds. 
In addition, solubility studies carried out on two benzodiazepine drugs (alprazolam and 
midazolam) in randomly methylated P-CD (Rameb) and 2-hydroxypropyl-P-CD (2-HP P-
CD) solutions showed a significant solubility enhancement factor. Attempts to prepare 
solid cyclodextrin complexes of alprazolam and midazolam proved to be unsuccessful as 
expected from phase solubility studies. The crystal structure of midazolam sesquihydrate 
prepared from aqueous solution by the pH adjustment method was solved. 
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CHAPTER 1: INTRODUCTION 
1.1 CYCLODEXTRINS 
The products of starch digestion by Bacillus macerans are known as cyclodextrins. 
These molecules were discovered by Villiers 1 in 1891 and were fully characterised by 
Schardinger.2 The structure of cyclodextrins (CDs) only came to be known 40 years 
after their discovery when Freudenberg et al. came to the conclusion by using data 
published by Karrer/ and Miekeley,4 that the cyclodextrins are made up of glucose 
units with a a-1,4 glycosidic linkages as shown in Fig 1.1(a). The structure of a-D 
glucose is shown in Fig 1.1(b). The digestion of starch by Bacillus macerans yields 
three different products which are systematically named as a-, P-, and y-CD. The 
three products differ in that they are made of 6, 7 and 8 a-D glucose units respectively 
as shown in Fig 1.2. The differences in the numbers of glucose units in the ring give 
rise to differences in both physical and chemical properties of the cyclodextrins. One 
of the differences in physical properties is the solubility in the aqueous solution. The 
solubilities of the native CDs increase in the order P- < a- < y-CD. The differences in 
the numbers of glucose units also give rise to differences in the radii of the 
macrocycles and the number of water molecules per CD molecule. The radii of the 
cavities are 5.7, 7.8 and 9.5 A for a-, p-, and y-CD and the crystal water contents at 
high humidity are 6.6, 12 and 17 water molecules per a-, p-, and y-CD molecule 
respectively. 5"6As shown in Fig 1.2, the glucose unit of the CD has hydroxyl groups 
on C(2), C(3) and C(6) which are accessible to functional group transformation. 7-9 A 
number of CD derivatives can be made by changing the functional groups at these 
positions. Only the P-CD derivatives are discussed here. 
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The common P-CD derivatives are heptakis(2,6-di-O-methyl)-P-CD (Dimeb ), 
heptakis(2,3,6-tri-0-methyl)- p-CD (Trimeb), randomly methylated P-CD (Rameb) 
and 2-hydroxypropyl P-CD (2-HPP-CD). Dimeb and Trimeb are crystalline while 
Rameb and 2-HPP-CD are amorphous. These P-CD derivatives have high aqueous 
solubility as well as greater ability to form inclusion complexes than their parent 
hosts. The solubilities of the methylated P-CD derivatives decrease with increase in 
temperature, while the hydroxypropylated derivatives follow a similar solubility 
pattern to the native CDs. 
CDs and their derivatives play a very important role in drug formulations in that they 
can be used to ( 1) stabilise drugs that are light or air sensitive, (2) improve dissolution 
rates and bio-availability of drugs, (3) reduce side effects and other unfavourable 
properties. 5'6' 10 
The toxicity profiles as well as the metabolic fate of cyclodextrins have been 
thoroughly investigated and well documented.5'6' 11. 12 It is believed that native CDs are 
quite safe for oral administration as most of the CDs are degraded by intestinal flora 
in the colon. The relative amounts of undegraded CD that are absorbed into the 
bloodstream are less than 2, 6 and 0.1 percent for a-, P- and y-CD respectively. 
Parenteral administration of native CDs and methylated CD derivatives results in 






Figure 1.1 (a) Two glucose units linked by a-1 ,4 glycosidic bond (a) Structure of 
glucose unit with the numbering scheme (H atoms are omitted) 
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Figure 1.2 a-, p-, and y-cyclodextrin 
1.2 CYCLODEXTRIN COMPLEXES 
Cyclodextrins are capable of forming inclusion complexes with vanous guest 
molecules having a size compatible with the dimension of the CD cavity. 5 The 
following methods are used for the synthesis of cyclodextrin complexes: 
( 1) Kneading: in which the CD is kneaded with a small amount of water followed by 
the addition of an appropriate amount of guest, (2) Co-grinding: this involves 
vigorous grinding of the CD and the guest drugs without addition of any solvent, and 
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(3) Co-precipitation: here both drug and CD are stirred together m solution, 
preferably using water as a solvent.6•13 
Depending on the properties of the guest molecules, complexes may or may not be 
formed using either of the preparation methods discussed above. Based on statistical 
data on the complexes published so far, supramolecular chemists were able to 
postulate the following essential conditions for complex formations: 5•14 •15 
• The size and the shape of the guest molecules- the size of the guest molecule must 
be compatible with the diameter of the cavity 
• The properties of the guest molecule- the guest molecule should be hydrophobic 
as the interior of the cavity is hydrophobic. 
1.3. PROPERTIES OF CDs AND THEIR COMPLEXES IN SOLUTION 
1.3.1 SOLUBILITY OF COMPLEXES 
This section will cover the theory of the phase solubility technique and its application 
to CD complexes. 
1.3.1.1 THEORY OF PHASE SOLUBILITY TECHNIQUE 
The classical review of phase solubility techniques by Higuchi and Connors16 has 
sparked a major experimental gathering of information on phase solubility studies. 
Such techniques are applied to various systems including the drug-CD system. 
Solubility measurements are generally carried out by adding an excess amount of 
solute (S) into several containers (normally flasks) containing different known 
concentrations of a complexing agent (L). The samples are brought to equilibrium by 
shaking and then analysed for their concentration of S by suitable means. 
4 
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The construction of what is known as phase solubility diagrams facilitates the analysis 
of solubility data. The phase solubility diagram is a plot of the total concentration of S 
in the solution vs. the concentration of L. The phase diagrams are classified into two 
classes, the A type (the solubility of S is increased by the presence of L) and the B 
type as shown in Figure 1.3. The A type diagrams are further subdivided into the 
following: 
• AL- This is observed if complexes of first order in L are formed e.g. SL, S2L, ... ,SmL 
• Ap- This is observed as a result of higher order complexes in L e.g. SL2, SL3, ••• ,SL" 
• AN- the physical meaning of a type AN diagram is unclear. 
The B type diagrams are subdivided into: 
• Bs -This indicates the formation of a soluble complex which eventually reaches its 
solubility-limit and further addition ofL results in the depletion ofS from solution, 
Be Insoluble complex formed. 16• 17 
The general chemical equation for the host-guest interaction can be written as follows: 
mS+nL ~ LnSm 1.1 
At equilibrium, the overall stability constants for the interaction can be defined as 18 
1.2 
where f3nm is the overall stability constant, [LnSm] is the concentration of the complex 
fonned, [L] and [S] are concentrations of complexing agent (ligand) and solute 
respectively. The overall stability constant f3nm is also related to the stepwise stability 










In the equations above L1 and S1 are the total concentrations of Land S respectively. So 
is the concentration of S in the absence of L. L1 and S1 are related to the overall 





The general expression given forms the basis for the analysis of phase solubility 
diagrams as well as the calculation of the stability constants. 
d!.,_ diagrams 
As mentioned earlier, AL type diagrams are observed when complexes of first order 
with respect to L are formed. 17 "26 In that case the overall equations 1.2, 1. 6 and 1. 7 
can be rewritten as: 
[LSm] 
/3Im = [L] (sr 
Lt = [L] + LLP1m[L] (sr 
I m 









A 1 fs L · 1· · h 1 Im/Jlm[So]m p ot o r vs. r IS mear wit s ope · ""' ; for a 1: 1 complex the slope is 
1 + L. Plm[So] 
dpdiagrams 
The Ap diagrams occur when complexes of higher order with respect to L are formed. 
For the purpose of calculating the stability constants, it is common practice to 
describe the Ap diagrams by assuming that only SL and SL2 complexes are formed. 
Based on the assumption described above, the total concentration of S and L in the 
reaction vessel can be expressed by equations 1.12 and 1.13 respectively 
1.12 
1.13 
Subtracting 1.12 from 1.13 followed by rearrangement yields the following: 
1.14 
where Q = L1 - 2(S1 -[SJ) 1.15 
If equation 1.14 is substituted into equation 1.12 and the resulting expression divided 




They-intercept of such a plot is 1.16 
cKI2Q m = _ ____!.!:.=..___ 
1-Kll[So] 
and the gradient is given by 1.17 
Both K 11 and K 1 ~ can be calculated from equations 1.16 and 1.1 7. 
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Type B diagram 
The calculation of the stability constants from the ascending part of the B5 diagram is 
similar to that for the type A diagrams. The descending part of both B5 and B1 can also 
be used to calculate the stability constants. In this case a certain stoichiometry of the 
complex is assumed in order to calculate the stability constants (Kmn) from the data 
available. On the B diagrams there are two points which are useful for calculating Knm 
(see Fig 1.4): point A which is a point of inflection and B, the solubility limit of the 
complex. 16' 1 7 
The stability constant for an n:m complex is given by 
1.18 
where [Sx] and[ Lx] are the concentrations of solute and complexing agent respectively 
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Figure 1.4 Type B diagram showing calculation of the stability constants 
1.3.1.2 SOLUBILITY DATA OF CD-DRUG SYSTEMS 
There is a vast number of publications dedicated to CD-drug systems. 19-52 This section 
merely gives a representation of some of the data. Table 1.1 shows the magnitude of 
interaction between CDs and some guest molecules. 
Table 1.1: Drug-CD interactions in solution derived fro~ phase solubility diagrams 
Guest Host Diagram Stability constant References 
Type K1:1 [M-1] K1:2 [M-1] 




13-CD AL 1190±105 28 
tolnaftate HPj3-CD(3%) Ap 1460±139 
HPj3-CD(8%) Ap 1860±165 
hydrocortisone !3-CD Bs 4792 1739 29 
psora len !3-CD AL 663 30 
Dimeb AL 603 
Trimeb AL 69.6 
oxazepam !3-CD AL 205 31 
pregnanolone HPI3-CD Ap 32 
pilocarpine HPI3-CD Ap 33 
a-CD Bs 
13-CD Bs 
y-CD Bs 34 





Table 1.1 Continued 
Anandamide HPI3-CD Ap 39419 12 36 
(arachidonyl Dimeb AL 74487 
ethanolamide) HPy-CD AL 15469 
furosemide 13-CD Bs 823.5 37 
clofibrate 13-CD Bs 1315 38 
HPI3-CD AL 
Dimeb AL 
propanidid HPI3-CD AL 39 
19-norprogesterone 13-CD AL 25 
HPI3-CD AL 
HEI3-CD AL 
miconazole a-CD AL 333 40 
13-CD AL 293 
y-CD AL 695 
HPI3-CD AL 363 
HEI3-CD AL 305 
haloperidol Dimeb AL 2435 41 
HPI3-CD AL 2112 
triamterene !3-CD AL 340 42 
ketoconazole 13-CD AL 43 
HPI3-CD AL 
gliclazide 13-CD Bs 1094 44 
naproxen a-CD AL 40 45 
!3-CD AL 1702 
y-CD AL 146 
HPa-CD AL 103 
HPI3-CD AL 283 
HPy-CD AL 187 
salicylic acid 13-CD Bs 666 46 
nifedipine 13-CD AL 77.9 22 
y-CD Ap 53.1 3.5 
Dimeb Ap 283.1 11.3 
Rameb Ap 184.9 5.8 
2HP(3-CD AL 77.2 
2HPy-CD AL 49.3 








triflumizole 13-CD AL 470 48 
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1.5 SOLID STATE PROPERTIES OF CD COMPLEXES 
1.5.1 THERMAL ANALYSIS 
Thermal analysis has been used m order to describe properties of many solid 
substances. In the pharmaceutical industry thermal analysis is used to measure thermal 
stability and the presence of volatile material in the sample. This section presents the 
thermal analytical techniques used to study CD complexes and the properties which 
are likely to be observed. 
1.5.1.1 DIFFERENTIAL SCANNING CALORIMETRY (DSC) AND 
THERMOGRAVIMETRIC ANALYSIS (TG) 
TG gives quantitative data for loss of mass as a function of temperature and DSC 
measures the amount of heat evolved or released by the sample during a temperature 
programme. 
CDs and their complexes generally lose their water contents below 1 00 °C. The water 
loss (dehydration) from the CD or CD complexes are characterised by endothermic 
peaks on the DSC traces in the region of 30 to 100 °C. 5 Both TG and DSC serve very 
important purposes in helping to characterise inclusion complexes. TG is mostly used 
to determine the water content of the CD or CD complexes. True inclusion complexes 
can be distinguished from a physical mixture of host and guest by DSC because the 
guest molecule is often retained in the host cavity until the CD decomposes.5·6 
The native CDs and their complexes decompose above 250 °C while the methylated 
derivatives such as Trimeb and Dimeb decompose at around 200 °C. 
12 
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1.5.1.2 THERMAL DEHYDRATION KINETICS 
Solid state reactions are characterised by the breaking down of one or more 
components into simpler atomic groupings.62 The general equation for the solid state 
reaction can be written as: 
1.21 
Cyclodextrin molecules and their complexes crystallise as hydrates; upon heating, 
water is released in the form of vapour. The decomposition reaction of CDs and their 
respective complexes can be represented by equations 1.22 and 1.23 respectively. 
1.22 
1.23 
Solid state kinetics of dehydration studies are carried out using thermogravimetric 
analysis. 63 There are two thermogravimetric methods that are used in studying 
reaction kinetics, namely isothermal and non-isothermal gravimetry. These methods 
are well developed and there are several reviews and monographs on this subject.62-66 
In this section only the isothermal gravimetric analysis is described. The interpretation 
of kinetic data is facilitated by the use of the Arrhenius equation: 
k = Aexp(-EafRT) 1.24 
where A is the pre-exponential factor, k is the rate constant, R is the gas constant, Tis 
the temperature and Ea is the activation energy. The most important parameter in 
equation 1.24 is the activation energy.66 The kinetic studies involve the measurement 




extent of reaction while m~o m0 and m1 are the mass of the sample at time t, initial mass 
and final mass respectively. The rate laws for solid state reactions in the integral form 
can be written as: 
f(a) = kt 1.25 
Table 1.2 shows the kinetic models which describe f( a) and these models are used to 
determine the mechanisms of the reaction. The determination is done by plotting/( a) 
vs. time using the a-time data. The model which gives the best linear fit is chosen to 
be the correct one. 
Table 1.2: Theoretical kinetic models for solid-gas reactions 
1. Acceleratory a-time curves 
P1 power law 
E1 exponential law 





3. Deceleratory a-time curves 
3.1 based on geometrical models 
R2 contracting area 
R3 contracting sphere 





3.3 based on "order of reaction" 
F1 first order 
F2 second order 
F3 third order 




[-ln(J -a) / 12 













The application of kinetics studies to cyclodextrins is still in its infancy. 
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Szafranek et al. 67-70 have carried out studies on P-CD hydrate, P-CD deuterate and P-
CD complexes. These authors have used non-isothermal gravimetric methods. It was 
found that the dehydration process for the P-CD hydrate followed a zero order 
mechanism with an activation energy of 65 kJ mol"1•67 
1.5.2 CRYSTAL STRUCTURE 
1.5.2.1 MOLECULAR CONFORMATION OF CYCLODEXTRINS AND THEIR 
COMPLEXES 
As previously stated in Section 1.1, CDs consist of a.-D glucose units in a 4C1 
conformation. The atoms in the glucose unit are numbered as shown in Fig 1.1 (b). In 
this section the structures of P-CD, its methylated derivatives (Dimeb and Trimeb) 
and y-CD are discussed. Generally, the 0(2) and the 0(3) atoms of the adjacent 
glucose units in a CD molecule form intn:Lmolecular hydrogen bonding, which results 
in the stability and rigidity of the macrocycle. There are various geometric parameters 
which are used to define the CD conformation namely: 71 
• Planarity of the 0(4) polygon, the root-mean-square deviation of 0(4) from the 
least-squares plane. 
• Tilt angle, the angle made by the least-squares plane through the 0(4) atoms and a 
plane through C(1), C(4), 0(4) and 0(4') of each glucose residue. 
• Torsion angle index: this measures the differences in conformation of each 
glucose unit and changes associated with complex formation. 
• The 0(4)···0(4') distances: these give a measure of distances between the 0(4) 
atoms of the adjacent glucose units. 
15 
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• Glycosidic angle: this defines the angle subtended at the 0(4) atom i.e the angle 
C( 4Gn)-04Gn-C(1 Gn+J). 
• The 0(2)···0(3 ') distances are characteristic of intramolecular hydrogen bonding 
in native CDs which maintains the round structure of the macrocycle. In Trimeb 
these distances are longer because there is no possibility of hydrogen bonding (see 
Table 1.3).72 
• Radius of the 0( 4) polygon: the average value of the distance from the centre of 
the polygon to each 0(4) atom. 
All the above geometric parameters for P-CD, y-CD, Dimeb and Trimeb are listed in 
Table 1.3. 
Table 1.3 :Geometrical data for cyclodextrin macrocycles: distances (A) and angles CO) 
Parameter P-CD73 y-CD74 Dimeb75 Trimeb76 
Tilt angle CO) 14(10) 19(9) 14(8) 20(25) 
Glycosidic angle CO) 118(1) 117(1) 117(1) 117(2) 
planarity ofthe 0(4) polygon (A) 0.16 0.09 0.44 0.11 
Radius of the 0(4) polygon (A) 5.0(0.2) 5.9(0.1) 5.1(0.2) 5.0(0.3) 
0(2)···0(3 ') distance (A) 2.9(0.1) 2.8(0.1) 2.9(0.1) 3.5(0.2) 
0(4)···0(4') distance (A) 4.3(0.1) 4.5(0.1) 4.4(0.1) 4.3(0.1) 
It is evident from the list of parameters that each macrocycle has unique geometric 
properties. The average radii of the polygons increase as the number of glucose units 
in the ring increases. 
16 
INTRODUCTION 
1.5.2.2 MOLECULAR PACKING OF CDs AND CD COMPLEXES 
Different CDs and their complexes have different crystal packing modes. In this 
section the packing modes of P-CD, y-CD, Dimeb and Trimeb are discussed. 
8-Cvclodextrin 
P-Cyclodextrin and its complexes crystallise m the following different packing 
modes: 
• Cage-type packing 
Cage-type packing (see Fig 1.5) has been observed in P-CD dodecahydrate, as well as 
in P-CD complexes with small guest molecules such as ethanol,77 ethylene glycol,78 
hydrogen iodide79 and methanol.79 All of the above mentioned complexes crystallise in 
the monoclinic space group P2 1• In P-CD dodecahydrate, 6.5 ofthe 12 H20 molecules 
are located in the cavity and the guest molecules in all other complexes are included 
in the cavity together with some water molecules. The P-CD molecules are packed 
along a 2-fold screw-axis resulting in a herringbone like structure; hence this packing 
mode is also referred to as 'herringbone'.80 In this packing arrangement, either side of 
the CD molecule is blocked by part of an adjacent CD molecule and the guest as well 
as the water molecules in the cavity are completely isolated. 
• Channel-type packing 
In this type of arrangement, P-CD complexes form head-to-head dimers as shown in 
Fig.l.6. The channel type complexes belong to one ofthe space groups PI, C2 or P2 1• 
The dimer unit in space group PI or C2 forms a linear endless channel. A zigzag 
channel is observed in crystals with space group P2,. P-CD complexes which pack in 
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a linear channel include those of benzocaine,81 m-iodobenzoic acid,82 3,3-
dimethylbutylamine,83 p-nitroacetanilide and many others. J3-CD complexes with 
carmofur, 84 iodoaniline, o-ethylaniline 85 and benzil 86 pack in a zigzag channel mode. 
Many of the channel J3-CD complexes which crystallise in the space group C2 contain 
disordered guests. 
• Layer-type packing 
The layer-type packing (Fig 1. 7) is observed when the guest molecule is too large to 
be fully enclosed in the cavity. All of the J3-CD complexes which form layer packing 
crystallise in the space group P21, for example J3-CD with triethylenediamine
84 and 
sulfathiazole. 87 In this type of arrangement both ends of the J3-CD cavity are closed by 
parts of the adjacent J3-CD molecules. There are also some layer structures which are 
composed of head-to-head dimer units of J3-CD. This has been observed in the J3-CD 
complex with 4-tert-butylbenzyl alcohol which crystallises in the space group 
C2221.
74 The bulk of the guest molecule is fully immersed in the cavity with its 
hydroxymethyl group protruding from the primary end of the cavity and forming 
intermolecular hydrogen bonding with the J3-CD molecule of the next layer. In this 
case both ends of the cavity are open to the intermolecular space ofthe next layer. 
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Figure 1.5 Cage-type packing found in the 13-CD complex with benzyl alcohol.
71 
( •) represent atoms of the guest and water molecules 
a 
a 
Figure 1.6 Channel packing arrangement found in the 13-CD complex with ibuprofen. 











Figure 1.7: Layer-type packing found in the P-CD complex with (S)-flurbiprofen.71 
( •) represent atoms of the guest molecules 
r-Cyclodextrin 
y-CD and its complexes crystallise in two crystal forms, namely cage- and channel-
type. The only known cage-type structure of y-CD is a hydrate which crystallises in 
the monoclinic space group P21•
70 In a complexed form, y-CD crystallises in a 
channel-type structure in which case the CD molecule is situated on a 4-fold rotation 
axis parallel to the unique axis c, as shown in Figure 1.8. The inside of the cavity is 
large and the included guest molecules experience diffusive motions. Both the 4-fold 
symmetry and the diffusion motion contribute to the statistical disorder of the guest 
molecules in the CD cavity making it difficult to model the guest. There are a few 
crystal structures of y-CD complexes in which the guest is fully resolved from X~ ray 







Fig 1.8: The channel structure ofy-CD-12-crown-4-inclusion complex.88 
(•) represent atoms of the guest molecules 
Dimeb 
Dimeb and its complexes known so far crystallise in the orthorhombic space group 
P212121• The structure of Dimeb exhibits a round macrocyclic conformation which is 
maintained by intramolecular 0(3)-H····0(2) hydrogen bonding. There are very few 
Dimeb complex crystal structures reported because it is very difficult to obtain 
crystals of good quality for X-ray diffraction. The molecular packing of the Dimeb 
complexes with the following guests is discussed: 2-naphthoic acid 89 p-iodophenol 
and p-nitrophenoe5 In the structure of the Dimeb complex with 2-naphthoic acid, the 
guest molecule is inserted in the cavity with its carboxylic group protruding from the 
0(6) side of the Dimeb molecule. This complex molecule packs in exactly the same 
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way as the uncomplexed Dimeb. It is surprising to note that the guest molecules in 
Dimeb complexes with both p-iodophenol and p-nitrophenol are not located in the 
cavity but rather in the interstitial sites, as shown in Figure 1.9. This led to the 
conclusion that the intermolecular space in the crystal structure is hydrophobic.80 
Fig 1.9 Crystal structure ofDimeb complex with p-nitrophenol.75 
( •) represent guest atoms and water molecules 
Trimeb 
Like Dimeb, Trimeb and its complexes crystallise in the space group P2 12121, but 
nevertheless the crystal modes of packing of these complexes differ significantly. All 
Trimeb complexes tend to form head-to-head packing modes giving rise to a zigzag 
channel-type structure as shown in Figure 1.1 0. The channels lie on a 2-fold screw 
axis. The guest molecules are never fully immersed in the Trimeb cavity, a large 
portion of the guest often protruding from the 0(2), 0(3) side of the macrocycle. 
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This has been observed in many of the structures of complexes reported in literature 
e.g biphenylacetic acid,90 flurbiprofen,91 naproxen,92 ibuprofen93 and p-iodophenol.94 
Figure 1.10 Crystal structure of Trimeb with p-iodophenol. 94 
( •) reperesent guest atoms and water molecules 
1.6 MOTIVATION AND OBJECTIVES OF THE STUDY 
The pharmaceutical industry has been experiencing a number of problems related to 
the unfavourable properties of some drugs, such as adverse side effects (e.g. 
gastrointestinal irritation) and poor aqueous solubility. In recent years the industry has 
turned to a "wonder molecule", namely cyclodextrin, with the aim of improving the 
properties of some pharmaceutically important drugs. 
Although it has been known for a long time that cyclodextrins can form inclusion 
complexes with various pharmaceutical compounds, the structural information 
gathered so far offers very little when it comes to systematising the nature and the 
driving forces of complex formation. It is usually difficult to predict the space group 
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in which the complex crystallises and the mode of host-guest interaction from the 
structure of the drug and that of a cyclodextrin, except in the case of y-CD where all 
complexes thus far investigated crystallise in the tetragonal space group P4212. 
Therefore, one of the aims of this project is to contribute to the database of CD 
inclusion complexes which could be used to formulate the theory of CD-drug 
interaction. 
The host CD molecules used in this project were P-CD, y-CD, Trimeb, Dimeb, Rameb 
and 2-HPP-CD. The drug molecules chosen for this project were two anti-
hyperlipoproteinemic drugs clofibric acid (I) and clofibrate (II), an anxyolitic drug 
alprazolam (III), and an anaesthetic drug midazolam (IV). Preliminary phase 
solubility studies were carried out to establish whether the delivery properties of 
midazolam and alprazolam could benefit from CD complexation. 
(Yo, ~ 





Both midazolam and alprazolam are benzodiazepine molecules. There are a number of 
publications on the CD inclusion ofbenzodiazepine molecules, based on NMR and 
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molecular mechanics studies.26'95 However, there are no detailed crystallographic data 
on such complexes. Therefore attempts were made to prepare single crystals of such 
complexes suitable for X -ray analysis .. 
In this project we emphasise the preparation and characterisation of the complexes 
prepared. The techniques employed in characterising the complexes are DSC, TGA, 
X-ray powder diffraction (XRD), ultraviolet spectroscopy (UV), infrared spectroscopy 
(IR) and single crystal X-ray studies. 
By characterising the complexes and solving the crystal structures one can obtain the 
following vital information: 
• Thermal stability of the complexes. 
• The mode ofhost-guest interaction. 
• Conformation of the included guest molecule. 
• The spatial distribution of water molecules in the crystal structure. 
• The parameters obtained from single crystal X-ray analysis can be used to calculate 
idealised XRD patterns which in turn are useful as standard references for 
comparison with experimental XRD patterns from bulk quantities of complexes 
prepared in the pharmaceutical industry. 
Another area of interest which is addressed here is the study of the kinetics of 
dehydration which can give information on the stability of the hydrated complexes. 
Such studies are carried out using isothermal methods of analysis. The kinetic 
parameters, in favourable cases, can be correlated with the structure of the complexes 
obtained from X-ray analysis. This is indeed a useful means of elucidating the 
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CHAPTER 2: EXPERIMENTAL 
2.1 MATERIALS 
The host compounds P-cyclodextrin, y-cyclodextrin, Trimeb, Dimeb, Rameb and HPP-
CD were obtained from Cyclolab, Hungary, and were used as received. 
The guest compounds clofibric acid and clofibrate were purchased from Sigma Chemical 
Co., Missouri, USA, while alprazolam and midazolam were obtained from South African 
Druggists International, Port Elizabeth, South Africa. 
2.2 PREPARATION OF COMPLEXES 
All complexes, except where otherwise stated, were prepared by the co-precipitation 
method which involved the addition of equimolar amounts of drug and CD to water. For 
the preparation of P-cyclodextrin and y-cyclodextrin complexes, the drug was added to a 
CD solution and the mixture was stirred for 12 h at 65 °C. Single crystals of these 
compounds were then obtained by filtering the hot solution with microfilters whose pore 
size was 0.45~-tm and allowing the solutions to evaporate. Single crystals grew in two to 
three days. 
Dimeb and Trimeb complexes were prepared by stirring the CD and drug solution at 
room temperature for 4 h. Their single crystals were prepared by filtering the solution 
with a 0.45 ~-tm micro filter followed by elevating the temperature of the solution to 50 °C 
in a tank with thermostatic control. The crystals were formed within a day. 
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2.3 THERMAL ANALYSIS 
2.3.1 THERMOGRAVIMETRIC ANALYSIS (TG) AND DIFFERENTIAL 
SCANNING CALORIMETRY (DSC) 
TG experiments are carried out to determine the weight loss of a sample as a function of 
temperature, when the sample is heated at a constant rate. The DSC experiments measure 
the enthalpy changes occurring when the inclusion compounds undergo dehydration, 
phase change or melt. These experiments were performed on a Perkin Elmer PC7 system. 
The scans were carried out at a heating rate of 10 oc min-1 under nitrogen gas purge with 
a flow rate of 30 ml min-1• The masses of the samples were in the range 3-5 mg and the 
programmed temperature runs were between 30 and 350 °C, unless otherwise stated. 
Samples for the TG runs were placed in open aluminium pans while vented aluminium 
pans were used for DSC samples. 
2.3.2 ISOTHERMAL TG 
Isothermal thermogravimetric experiments were also carried out to determine the kinetics 
of dehydration for selected CD complexes. This was performed on the PC7 system by 
rapidly heating the sample to a required temperature in the range 35-70 °C. Samples used 
in this experiment were microcrystalline powders with particle size in the range of 10-
1 OO!Jm, obtained by complex crystallisation from rapidly stirred solutions. Mass losses 
measured with time were used to obtain a (extent of reaction) vs. time curves which were 
analysed using kinetic models1 to seek the best linear fits over the a-range ofO.OS-0.95. 
33 
EXPERIMENTAL 
2.4. ULTRA VIOLET SPECTROPHOTOMETRY (UV) 
Since cyclodextrins are UV inactive, UV plays an essential role m determining the 
amount of drug present in a specific mass of the sample or in the CD solution, provided 
the drug has an appropriate UV spectrum. In this study UV was used for determining the 
stoichiometry of the prepared complexes as well as for the phase solubility studies. 
• Determination of complex stoichiometry 
The stoichiometry was determined in conjunction with the TG results. A known mass of 
the sample was dissolved in a water-ethanol solution (40:60 by volume) followed by the 
measurement of the absorbance. The concentration of the drug in the solution was 
calculated using the Beer-Lambert law, which in tum determines the percentage content 
of the drug in a specific sample. 
• Phase solubility studies 
Phase solubility studies were carried out to measure the effect of cyclodextrin on the 
solubility of the drug. The measurements of the amount of drug dissolved in a CD 
solution were done using UV spectrophotometry. This topic is discussed in detail in 
Chapter 6. Absorbance measurements were performed on a Philips PU8700 UV/vis 
spectrophotometer in the range 200-400 nm at scanning rate of 200 nm min-1• 
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2.5 INFRARED SPECTROSCOPY (IR) 
The formation of an inclusion compound is known to have an effect on the spectroscopic 
properties of the guest molecule.2'3 Such effects can be evaluated by comparing the 
spectroscopic properties of pure drug to that of the complexed drug. In this study IR was 
used to determine the effect of CD complexation on the C=O stretching frequency of 
some guest molecules. Infrared spectra were recorded on a Perkin Elmer 983 IR 
spectrophotometer. Samples were prepared by grinding the material in nujol mull® and 
then placing the mull between two sodium chloride plates. 
2.6 X-RAY POWDER DIFFRACTION (XRD) 
XRD patterns were recorded on a Philips PWI 050/80 vertical goniometer equipped with 
a PW1394 motor control unit. Ni-filtered CuK.a radiation (A.= 1.5418A), generated by a 
Philips PW1130/90 generator, was used. The samples were packed into aluminium 
sample holders and scanned over the 28 range of 6-40° at intervals of 0.1° with 2s counts. 
2.7. CRYSTAL STRUCTURE ANALYSIS 
Single crystals of suitable size (between 0.2 and 0.5 mm in all dimensions) were selected 
for diffractometry experiments on the basis of their ability to extinguish plane-polarised 
light uniformly. All crystals were mounted onto glass fibres using cyanoacrylate 
adhesive. Unstable crystals, such as those of complexes with native cyclodextrins, were 




Preliminary unit cell data and space group information were obtained from oscillation, 
Weissenberg and precession photographs taken on a Stoe goniometer using Ni-filtered 
CuKa radiation (A.= 1.5418A), generated by a Philips PW1120 generator operating at 
20mA and 40kV. 
Data-collections were carried out on a Nonius Kappa CCD diffractometer, using graphite-
monochromated MoKa radiation (A.= 0.71069A). Most of the intensity data were 
recorded at 293K except those for CETMB, which were collected at 173 K. Details on the 
data-collection strategies are given for each structure in their respective chapters. 
2.8 COMPUTATION 
2.8.1 CRYSTAL STRUCTURE DETERMINATION AND REFINEMENT 
All crystal structures of complexes were solved by isomorphous replacement methods 
using atomic co-ordinates for the non-hydrogen atoms of cyclodextrins in the 
isomorphous structures. The refinement was performed using SHELXL-934 which 
employs full-matrix least-squares refinement on F2• The midazolam structure was solved 
by direct methods using program SHELXS-865 and the refinements were performed using 
the SHELXL-934 program. The reliability of the calculated structure model is measured 
by the R-factor. The values that will be quoted and which serve as a good measure for the 
reliability of the model are the residual index R" which is a measure of the agreement 
between the calculated (Fe) and observed (Fa) structure factors, and wR2 based on the 
refinement on F2. 
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EXPERIMENTAL 
These are given by 
where w is the weight (a and b are refined for each structure) 
The goodness of fit (S) based on p2 serves as the basis for examining the analysis of 
variance for the F2 values and is defined by: 
where n is the number of reflections and p is the total number of refined parameters. 
2.8.2 MOLECULAR AND CRYSTAL PACKING DIAGRAMS 
Molecular and crystal packing diagrams were produced using a PC version of PLUT0.6 
The sizes of interstitial channels formed by the host were visualised using the program 
MOLMAP.7 The Cambridge Structural Database (CSD)8 was extensively used to obtain 
atomic co-ordinates of the structures which are isomorphous to those of complexes 




2.8.3. CALCULATED XRD PATTERN 
The calculated XRD pattern was obtained using the program LAZYPUL VERIX9 running 
on a personal computer in a DOS environment. The space group data, unit cell 
parameters, co-ordinates of the atoms and their respective thermal parameters were used 
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CHAPTER 3: P-AND y-CD COMPLEXES OF CLOFIBRIC ACID 
3.1 INTRODUCTION 
The anti-hyperlipoproteinemic (cholesterol-lowering) drugs are among many 
pharmaceutical agents that are poorly soluble in water. Some studies on inclusion 
complexes of anti-hyperlipoproteinemic drugs have been reported. 1·2 Clofibrate and 
fenofibrate are two of the anti-hyperlipoproteinemic drugs that have been studied as 
guest molecules for complexation with CDs. Anguiano-Igea et a1.1 characterised the 
P-CD inclusion complex of clofibrate using XRD, DSC and IR spectroscopy. 
Although CD inclusion compounds were prepared and partially characterised, no 
single crystal X-ray studies were conducted on these inclusion complexes to establish 
the exact mode of inclusion. In this study, clofibric acid (I), that is 2-( 4-
chlorophenoxy)-2-methyl propionic acid, which is also poorly soluble in water, was 
investigated as guest molecule for inclusion into P-CD and y-CD. Clofibric acid is an 
anti-hyperlipoproteinemic drug which is known to reduce triglyceride and cholesterol 
concentration in the serum. 3 It is also the active metabolite of clofibrate. Clofibric 
acid has been reported as crystallising in the monoclinic space group P21/n where it 
occurs as hydrogen-bonded cyclic dimers.4 This strong intermolecular hydrogen 
bonding results in poor solubility and slow dissolution rate, which are indeed the rate-
limiting steps in gastro-intestinal absorption. 
I 
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3.2 PREPARATION OF COMPLEXES 
Complexes were prepared as described m section 2.2; here we report the 
characterisation of the ~-CD and y-CD complexes of clofibric acid, which will be 
referred to hereafter as CO BCD and COGCD respectively. 
3.3 THERMAL ANALYSIS 
Both COBCD and COGCD were characterised by TG and 
DSC as described in section 2.3. The TG-DSC traces of COBCD and COGCD are 
shown in Figures 3.1 and 3.2 respectively. Characteristic DSC temperatures and 
estimated water contents from TG are listed in Table 3.1. 
Table 3.1 TG-DSC data for COBCD and COGCD 
Complex Event Onset(T I °C) Peak (T/ °C) %H20 H20 molecules 
(DSC) per CD molecule 
COB CD EndoA 48 66 10.1 8.4 
EndoB 104 110 
Exo C 302 309 
COGCD EndoA 50 75 15.6 15.5 
ExoB 301 309 
Endo = endotherm; Exo = exotherm 
The first stage in the decomposition of the complexes is dehydration which occurs 
from 40-99 oc. For COBCD, dehydration occurs in two steps as indicated by an 
inflection point on the TG trace and as distinct endotherms A and B in the DSC 
traces. This is followed by gradual mass loss with major decomposition occurring 
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exothermically from 299-329 oc (peak C). COGCD behaves similarly, except that 
what appears as a two-step process in TG is reflected only as a single endotherm 
(Peak A) in the DSC. 
25 100 
~ 20 80 
..... ~ 
15 "' ~ 60 ~ .S2 u.. DSC ..... - 10 "' 40 at ~ 
5 20 
0 
30 80 130 
. 0 
180 230 280 330 
Temperature 1 •c 
Figure 3.1 TG-DSC Traces for the complex COBCD 
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Figure 3.2 TG-DSC Traces for the complex COGCD 
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3.4 STOICHIOMETRY OF THE COMPLEXES 
The stoichiometries of the complexes were determined by UV spectrophotometry and 
TG analysis. The chemical formulae for the complexes are shown in Tables 3.3 and 
3.8. Both the COBCD and COGCD complexes contain 1:1 stoichiometric amounts of 
host and guest with 8.4 and 15.5 HzO molecules per CD molecule respectively. 
3.5 INFRARED SPECTROSCOPY (IR) 
Since clofibric acid is a carboxylic acid, it was decided to assess the effect of complex 
formation on the carbonyl stretching frequency of clofibric acid. The carbonyl 
stretching frequency of pure clofibric acid was measured and found to occur at 1 706 
cm-1• The carbonyl stretching frequency of the complexed drug in COBCD is 
displaced to 1730 cm-1, and in COGCD to 1729 cm-1• It is evident that the v(C=O) of 
the complexed drug is significantly higher than in pure clofibric acid which suggests 
that the C=O bond is stronger in the complexed drug than in the uncomplexed acid. 
These shifts are similar to those observed by Wei et al.5 from the IR spectra of 
tolbutamide complexes with permethyl-P-CD. 
3.6 X-RAY POWDER DIFFRACTION 
The complexes were characterised by XRD as described in section 2.6. This technique 
is very useful in helping to distinguish complexes from their respective physical 
mixtures. This is clearly illustrated in the XRD traces of COBCD, COGCD and their 
corresponding physical mixture of the respective CD with clofibric acid in Figure 3.3. 
In each case, the XRD pattern ofthe complex differs from that of the physical mixture 
allowing one to conclude that the complex represents a new crystalline phase. 
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A careful analysis of the XRD trace for COGCD reveals that the XRD pattern is 
relatively 'simple' in that it has few peaks. This is characteristic of compounds belonging 






















--1:1 physical mixture 
6 16 26 36 
2 Theta [degree] 
COG CD 
-1:1 physical mixture 
6 16 26 36 
2 Theta [degree] 
Figure 3.3 The XRD traces of (a) COBCD and 1:1 mixture of clofibric acid and J3-CD 
( b) COGCD and 1: 1 mixture of clofibric acid and y-CD 
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3.7 CRYSTAL STRUCTURE ANALYSIS 
3.7.1 DATA-COLLECTION 
X-ray diffraction data for both COBCD and COGCD were collected on a Nonius 
Kappa CCD diffractometer using graphite-monochromated MoKa. radiation at 293 K. 
A crystal of COBCD with dimensions 0.2 x 0.3 x 0.3mm was mounted on a glass 
fibre. The crystal was then covered in a cyanoacrylate adhesive to prevent cracking 
due to loss of water of crystallisation. A COGCD crystal of dimensions 0.3 x 0.4 x 
0.3mm was treated in the same way. The detector to crystal distances were 50mm for 
both data-collections. A scan of 1.0° per image in ~ was used in the range -120 to 
120° for COBCD and -160 to 142° for COGCD. 
3.7.2 COBCD COMPLEX 
3. 7.2.1 STRUCTURE DETERMINATION AND REFINEMENT 
The crystal structure of COBCD was solved by the isomorphous replacement method 
using co-ordinates of the non-hydrogen atoms (excluding primary oxygen atoms, 
0(6)) ofthe host CD in the isomorphous P-CD complex ofibuprofen.6 
The structure was refined by full-matrix least-squares refinement using the SHELXL-
93 program7 with subsequent location of remaining non-hydrogen atoms from the 
electron density map. The atoms 0(6Gl), 0(6G2), 0(6G4), 0(6G5) and 0(6G6) were 
found to be disordered, which means that each of them occupies at least two different 
sites. The site occupancy factors ofthe 0(6) atoms are shown in Table 3.2. 
All oxygen atoms except the disordered 0(6) atoms were refined anisotropically with 
full site occupancy factor. Hydrogen atoms bonded to the carbon atoms of the host 
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were inserted in idealised positions (C-H distance of 0.98A) and their common 
assigned temperature factor was allowed to refine freely, converging to Uiso = 0.07A2• 
Some electron density peaks (:::;1.05 eA-3) were observed in the difference Fourier 
· map corresponding to the guest molecule in the P-CD cavity. These peaks could not, 
however, be interpreted as a meaningful representation of the guest drug molecule due 
to crystallographic disorder. 
The structure refinement accounted for 7.0 H20 molecules per CD molecule out of 
8.4 H20 estimated from TG analysis. Since the guest molecule could not be resolved, 
the refinement converged to a relatively high R1-value of 0.12 for I>2cr(I). The 
maximum and minimum residual electron densities were 1.05 and -0.52 eA-3 
respectively. Final fractional co-ordinates for all atoms of the host and water 
molecules in the COBCD complex are given in Appendix A on the appended diskette 
in ASCII format under the filename COBCD.TEX. Appendix B; also on diskette 
gives a full listing of observed (Fo) and calculated (Fe) structure factors. These are 
given under the filename COBCD.SFT. 
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3. 7.2.2 HOST-GUEST INTERACTION AND CRYSTAL PACKING 
The numbering scheme for P-CD is shown in Figure 3.4 and that of the glucose 
moiety is shown in Figure 1.1 (b). P-CD molecules in CO BCD crystallise as head-to-
head dimers through the formation of intermolecular hydrogen bonds between the 
0(3) atoms as shown in Figure 3.5. The intermolecular (intradimer) bonding distances 
are listed in Table 3.4. The dimers are stacked on top of each other along the c-axis 
yielding a channel-like structure. Figure 3.6 shows the channel packing of P-CD in 
the COBCD complex. 
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Figure 3.4 The P-CD molecule with its numbering scheme 
A 
Figure 3.5 A view down [010] of the P-CD dimer. Oxygen atoms of the host and 
those of the water molecules are shown as open circles 
The guest drug molecule is located inside the cavity, but it is disordered and could not 
be modelled to give a meaningful chemical structure. The electron density peaks 
located in the cavity, having a maximum value of about 1.05 eA·3 reveal the 
approximate position of the guest molecule. 
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The disposition of these electron density peaks is shown in Fig 3.7. The disorder of 
the guest molecule is attributed to the highly diffusive state of the guest within the 
channel. Such disorder has been observed in other ~-CD complexes which pack in a 
similar mode.6•8-10 The water molecules of crystallisation form a hydrogen bonding 
network which facilitates the formation of infinite planes by the dimers as shown in 
the stereodrawing in Figure 3.8. Table 3.5 lists the hydrogen bonds between the water 




Figure 3.6 The channel packing mode of ~-CD molecules in COB CD. Oxygen atoms 
of the host and those of the water molecules are shown as open circles 
Figure 3. 7 A Stereo view of the largest electron density peaks representing the guest 
molecule 
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3. 7.2.3 CONFORMATION OF THE HOST MOLECULE 
All seven a-D-glucose sub-units of the f3-CD molecule exhibit a 4C1 chair 
conformation. The primary hydroxyl group of the G(4) glucose unit is in a (-)-gauche 
conformation while the rest are in a (+)-gauche conformation. Geometric data such as 
radii of the 0(4) heptagon, tilt angle, glycosidic angle, the 0(4)···0(4) distances and 
the deviation of the 0( 4) atoms from their least-squares plane are given in Table 3.6. 
The tilt angles listed in Table 3.6 are all positive which means that the primary side of 
all seven glucose units leans toward the centre of the cavity. As a result, the P-CD 
molecule adopts a cone-like structure with the secondary side wider than the primary 
side. The conformation of the P-CD macrocycle is maintained by intramolecular 
0(3Gn)···0(2Gn+I) bonds. This is similar to the situation in other P-CD complexes 
reported in literature.6'11 -13 The 0(3Gn)···0(2Gn+I) hydrogen bond distances are listed 
in Table 3.7. 
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Table 3.6: Geometric data for the ~-CD molecule in COBCD 
The glycosidic oxygen angle C4Gn-04Gn-C1 Gn+J (0 ) and the torsion angle index (0 ) 
C( 4G 1 )-0( 4G 1 )-C( 1 G2) 118.9(5) G1 113.5 
C(4G2)-0(4G2)-C(1 G3) 119.5(4) G2 125.5 
C( 4G3 )-0( 4G3 )-C(l G4) 117.9(4) G3 119.2 
C( 4G4)-0( 4G4)-C(1 G5) 118.6(4) G4 121.1 
C( 4G5 )-0( 4G 5 )-C( 1 G6) 118.3(5) G5 124.2 
C( 4G6)-0( 4G6)-C( 1 G 7) 119.0(4) G6 123.5 
C( 4G 7)-0( 4G 7)-C( 1 G 1) 118.9(5) G7 120.7 
Glucose Unit Tilt angle Radius of 0(4Gn) ... 0(4Gn+J) Deviation 
(0) heptagon (A) (A) 
(A) 
G1 2.6(3) 5.06(1) 4.34(1) 0.060(5) 
G2 8.0(2) 5.22(1) 4.40(1) -0.042(5) 
G3 6.5(3) 5.02(1) 4.40(1) -0.043(5) 
G4 1.6(2) 4.97(1) 4.42(1) 0.069(5) 
G5 4.1(2) 5.08(1) 4.32(1) -0.002(5) 
G6 7.2(2) 5.11(1) 4.37(1) -0.086(5) 
G7 0.6(2) 4.94(1) 4.47(1) 0.040(5) 
All parameters in table are defmed in section 1.5.2.1 
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3.7.3 COGCD COMPLEX 
3. 7.3.1 STRUCTURE DETERMINATION AND REFINEMENT 
The structure of COGCD was solved using co-ordinates for the non-hydrogen atoms 
(excluding the 0( 6) atoms) of the y-cyclodextrin molecule in the isomorphous y-
CD·12-crown-4-LiSN complex. 12 The refinement was carried out using the SHELXL-
93 program. 7 The missing atoms of the host as well as the H20 molecules were 
located from subsequent electron density maps. Some of the oxygen atoms of the host 
CD were found to be disordered over two sites each. All non-hydrogen atoms were 
assigned anisotropic temperature factors. The refinement of this structure proved to be 
unsuccessful since the guest molecule could not be modelled beyond the diffuse 
electron density peaks in the CD cavity. Thermogravimetric analysis of the complex 
gave a weight loss which corresponded to 15.5 water molecules per CD molecule but 
only 6.3 H20 molecules (which mainly occupy interstitial sites) were accounted for in 
the refinement. The data-collection and refinement details for COGCD are listed in 
Table 3.8. Final fractional co-ordinates for all atoms of the complex are given in 
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Appendix A on the appended diskette in ASCII format under the filename 
COGCD.TEX. Appendix B is also on diskette and is a full listing of observed (Fo) and 
calculated (Fe) structure factors. These are given under the filename COGCD.SFT. 
3. 7.3.1 HOST-GUEST INTERACTION AND CRYSTAL PACKING 
In the COGCD crystal structure, three y-CD molecules are stacked together in head-
to-head, tail-to-tail and head-to-tail packing modes along the c-axis forming a 
channel-type structure. Figure 3.9 shows the three y-CD molecules stacked together. 
In each y-CD molecule, A, B and C, two glucopyranose residues form an asymmetric 
unit, from which the complete molecule is generated by the four-fold rotation axis. 
The glucose units are numbered as G1, G2 for molecule A, G3, G4 for molecule B 
and G5, G6 for molecule C. The atoms are numbered as A(nm) where A represents 
the atomic symbol, n is based on the numbering scheme for the glucose moiety as 
shown in Figure 1.1 (b) ( Chapter 1 ), and m is the number of the glucose moiety. The 
host and guest are centred on a four-fold rotation axis in a similar way to that shown 
in Figure 1.8. Molecules A and C have the same orientation and molecule B has the 
opposite orientation. Several intermolecular hydrogen bonds are formed between the 
secondary hydroxyl groups of A and B, the primary hydroxyl groups of B and C, and 
the primary hydroxyl groups A and the secondary hydroxyl groups of molecule C. 
This gives an endless channel-like structure, which accommodates clofibric acid and 
some water molecules. The guest molecule could not be resolved to reveal the exact 
mode of complexation due to crystallographic disorder exacerbated by the 
requirement of the four-fold symmetry of the contents of the cavity. The interstitial 
sites also assume a channel-like shape and are filled with water molecules as shown in 
Figure 3.10. 
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Figure 3 .I 0 Crystal packing of the COGCD complex viewed down [0 10] with 
interstitial sites occupied by water molecules 
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3. 7.3.3 CONFORMATION OF HOST MOLECULE 
All glucose units of the three different y-CD molecules are m the 4C1 chair 
conformation. Table 3.9 list all important geometric parameters which describe the 
conformation of the macrocycle. The inter-glucose (glycosidic) bond angles range 
from 115.0(4) to 116.7(4)0 • The distances of the 0(4) atoms from the centre of gravity 
of the y-CD macrocycle are in the range 5.82 to 5.90A . This is defined as the radius 
of the octagon for y-CD. The tilt angles range from 3.9-17.2°. The positive signs of 
these tilt angles indicate that the glucose moieties of all three y-CD molecules are 
inclined with their primary side slightly turned toward the centre of the macrocycle. 
The round shape of the macrocycle is maintained by the formation of intramolecular 
hydrogen bonds between the secondary hydroxyl groups reflected in the 0(2)"·0(3) 
distances between the neighbouring glucose residues. The intramolecular hydrogen 
bond distances are listed in Table 3.10. 
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Table 3.9: Geometric parameters for the y-CD molecules in COGCD 
The glycosidic oxygen angle C4Gn-04Gn-C1Gn+l (0) and the torsion angle index (0) 
Glycosidic angle e) M G (0) 
C(41 )-0( 41 )-C(12') 116.7(5) A G1 113.5 
C(42)-0(42)-C(11) 116.7(4) G2 125.5 
C(43)-0( 43)-C(14 ') 116.1(4) B G3 119.2 
C( 44 )-0( 44 )-C( 13) 116.1(4) G4 121.1 
C( 45)-0( 45)-C( 16 ') 115.0(5) c G5 124.2 
C( 46)-0( 46}-C( 15) 115.0( 4) G6 123.5 
M G Tilt angle Radius ofheptagon 0(4Gn) ... 0(4Gn+J) Deviation 
(0) (A) (A) (A) 
A G1 13.7(2) 5.88(1) 4.49(1) -0.004(4) 
G2 3.9(1) 5.87(1) 4.50(1) 0.005(5) 
B G3 15.6(3) 5.85(1) 4.50(1) -0.003(4) 
G4 13.3(2) 5.83(1) 4.50(1) 0.004(4) 
c G5 17.2(2) 5.90(1) 4.49(1) -0.015(4) 
G6 5.8(2) 5.82(1) 4.49(1) 0.017(5) 
All geometric parameters are defined in section 1.5.2.1, M = y-CD molecule and G=Glucose unit 
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Glucose unit 0"·0 
G1 0(21 )"·0(32) 
G2 0(22) .. ·0(31 ') 
G3 0(23) .. ·0(34) 
G4 0(24) .. ·0(33 ') 
G5 0(25) .. ·0(36) 
G6 0(26) .. ·0(35') 








Water molecules play an essential role in stabilising the crystalline structure of 
cyclodextrin inclusion compounds. Complex water content as well as the nature and 
the rate of dehydration affect properties such as cohesive strength and stability under 
storage. The kinetics of dehydration of the two complexes (COBCD and COGCD) 
and their respective host compounds ~ere investigated by isothermal 
thermogravimetry. It was of particular interest to compare the activation energies of 
dehydration of the complexes with those for the uncomplexed hydrated parent CDs. 
In this section we report the results of the kinetics of dehydration in relation to crystal 
structure. 
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3.8.1 RESULTS FOR THE KINETICS OF DEHYDRATION 
The kinetics of dehydration studies were carried out over the temperature range of 35-
70 °C. The a.-time curves for COBCD and COGCD are best described by the D3 
(three dimensional diffusion-controlled) model, whereas those of P-CD and y-CD 
hydrates are best described by the F1 (first order) and F2 (second order) kinetic 
models respectively. Figure 3.11 shows a representative a.-time curve for COB CD at 
55 °C. The Arrhenius (Ink vs. liT) plots for the compounds studied were linear over 
the investigated temperature range as shown in Figure 3.12. Kinetic data for the 
dehydration of COBCD, COGCD, P-CD·12.5Hz0 and y-CD·16.8Hz0 are listed in 
Table 3.11. The activation energies for the dehydration of the complexes are 
significantly lower than those of their corresponding parent hydrated CDs. It should 
be noted that the activation energy (Ea) obtained here for the dehydration of P-
CD·12.5H20, 64 ± 2 kJ mor1, compares favourably with the value 65.7 ± 3.1 kJ mor1 
obtained earlier, 14 although the non-isothermal methods used led to the conclusion 
that the dehydration is a zero-order process. On the other hand, first-order dehydration 
kinetics were reported for the hydrated P-CD from the analysis of diffraction data 
measured from a single crystal exposed to a range of relative humidities. 15 In any 
event the use of 64 ± 2 kJ mor1 for the dehydration of P-CD hydrate obtained in this 
study seems to be justified in view of the insensitivity of derived Ea values to the 
reaction order and the fact that it is being compared to the Ea values for other 
compounds obtained under the same conditions. 
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Table 3.11 Kinetic parameters for dehydration of complexes COBCD and COGCD 
and their corresponding uncomplexed parent CD hydrates. 
Species Kinetic model Ea/ Regression coeff. 
for dehydration kJ mor1 Arrhenius plot 
COB CD D3 50± 2 0.9911 
COGCD D3 43 ± 1 0.9973 
~-CD·12.5H20 F1 64 ± 2 0.9978 
y-CD·16.8H20 F2 58 ±4 0.9951 
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Figure 3.12: Arrhenius plots for (a) COBCD, (b) COGCD, (c) ~-CD hydrate and (d) 
y-CD hydrate 
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3.8.2 KINETICS OF DEHYDRATIONS IN RELATION TO CRYSTAL 
STRUCTURE 
As described in 3.7.2.2 and 3.7.3.2, both COBCD and COGCD complexes pack in 
channel mode and the channels are occupied by water molecules as shown in Figures 
3.13 and 3.10 respectively. The program MOLMAP16 was used to examine the water-
filled channel topologies. The program MOLMAP reads a SHELX-93 input file and 
allows one to plot slices through the unit cell at constant intervals. Atoms of the water 
molecules were removed from the input file, leaving the host atoms which were 
assigned their van der Waals radii. This revealed the continuity and unconstrained 
nature of the channels along the z-direction in the crystals. The channel cross-
sectional areas vary between 34-57 A2 in COBCD and 44-97 A2 in COGCD. Thus, 
migration of H20 molecules along these channels should be unimpeded by the host 
CD molecules in both complexes. These results are consistent with the finding that the 
dehydration of both COBCD and COGCD follow a diffusion-controlled kinetic 
model. A detailed study of the packing in the P-CD hydrate structure15 showed that 
there are no diffusion paths for H20 molecules in the static structure and that 
dehydration must involve some conformational flexure of the host molecule to create 
such pathways. This crystal structure and that ofy-CD hydrate are of a 'cage' type17 
with water molecules 'locked' in the interstitial cavities and within the CD cavities. It 
is therefore reasonable to conclude that the lower activation energy obtained for the 
dehydration of complexes COBCD and COGCD as compared to their parent CD 
hydrates are consistent with the location of the water molecules in unobstructed 
channels, which could facilitate water escape from the crystal. P-CD and y-CD 
complexes frequently crystallise in the respective space groups C2 and P4212 and we 
predict, on the basis of their isomorphism with COBCD and COGCD, that their 
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dehydration will also be characterised by relatively low activation energies. 
Figure 3.13 Projection of the crystal structure of COB CD parallel to the host channel, 
showing interstitial water molecules 
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CHAPTER 4: DIMEB AND TRIMEB COMPLEXES OF CLOFIBRIC ACID 
4.1 INTRODUCTION 
The significantly greater solubility of methylated P-CDs as compared to their parent CDs 
makes them ideal for pharmaceutical application. These molecules are also known to 
have higher complexing ability than their corresponding native CDs. Since the guest 
molecules in COGCD and COBCD are disordered, as reported in Chapter 3, it was 
decided to consider studying inclusion complexes of clofibric acid with methylated CDs 
which are generally known to yield ordered structures. The complexes were prepared as 
reported in section 2.4. In this chapter we report data for the solid complexes of Dimeb 
and Trimeb with clofibric acid, which are determined mainly by thermal analysis as well 
as X-ray structure analysis. The Dimeb and Trimeb complexes of clofibric acid will be 
referred to as CODMB and COTMB respectively. 
4.2 THERMAL ANALYSIS 
The DSC-TG traces of CODMB and COTMB are shown in Figures 4.1 and 4.2, and the 
data are listed in Table 4.1. The dehydration ofboth complexes is endothermic (Endo A). 
The anhydrous CODMB complex undergoes a phase transition at 151.4 °C (Endo B) 
followed by decomposition at 206 °C (Endo C). 
The dehydration process of COTMB occurred over a wide temperature range despite the 
fact that COTMB contains only about 1.5% H20 by mass as determined by TG. 
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Other interesting features were observed on the DSC traces of COTMB; the anhydrous 
COTMB complex undergoes an endothermic phase change (endo B), recrystallization, 
and finally melting which is represented by peak C. The proposed phase transition is 
consistent with zero mass loss (from TG) over the temperature range which includes 
peaks Band C. To confirm the nature ofthe phase transition, X-ray diffractograms were 
1 .f-hoJ ho..d bQQS\ +~tn o.l/o~.Jf~ +o cool .b o.m ~i enr 
recorded for COTMB samples12?eated to approximately 100, 135 and 200 ocLThe first ~QPtftrAture • 
two samples yielded different X-ray powder patterns, thus confirming the existence of 
two distinct crystalline phases, while the last yielded a diffuse pattern only, indicating 
that the final residue was essentially amorphous. 
Table 4.1 DSC-TG data for CODMB and COTMB 
complex Event Onset (T I °C) Peak (T/ °C) %H20 H20 molecules per CD 
(DSC) (TG) molecule 
CODMB EndoA 54.1 76 5.9 5.4 
EndoB 148.9 151.4 
EndoC 201 206.5 
COTMB EndoA 30 45 1.5 1.4 
EndoB 129 132 
EndoC 145 147 
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FIGURE 4.1: TG-DSC traces for the CODMB complex 
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FIGURE 4.2 TG-DSC traces for the COTMB complex 
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4.3 STOICHIOMETRY OF COMPLEXES 
The stoichiometries of the complexes were determined by using both TG and UV 
spectrophotometry. TG was used to determine the amount of water present in the 
complex while UV spectrophotometry was used to determine the drug content. Both 
complexes have 1: I drug-CD molar ratio and their H20 contents are 5.4 and 1.4 H20 
molecules per CD molecule for CODMB and COTMB respectively. The full chemical 
formulae for the complexes are listed in Tables 4.2 and 4.3. 
4.4 INFRARED SPECTROSCOPY 
Infrared spectroscopy was also used to study the complexes CODMB and COTMB. The 
C=O stretching frequencies of the complexed drugs in CODMB and COTMB are 
displaced to 1734 and 1726 cm·1 respectively from the value of 1706 cm·1 for the drug 
itself. These shifts are similar to the ones observed in the IR spectra of COBCD and 
COGCD (Chapter 3). The crystal structure solution for COTMB has helped to clarify 
what causes C=O stretching frequency shift (see section 4.5.5). The host-guest interaction 
as well as molecular packing in COTMB are discussed in detail in section 4.5. 
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4.5 X-RAY STRUCTURE ANALYSIS 
4.5.1 DATA-COLLECTION 
X-ray diffraction data for both CODMB AND COTMB were collected on a Nonius 
Kappa CCD diffractometer using graphite-monochromated MoKa radiation at 293 K. For 
CODMB a single crystal was mounted on a glass fibre. Since the complex has small 
water content, the crystal was stable and no special treatment was necessary. A crystal of 
COTMB was treated in the same way. Crystal data and data-collection strategies for the 
CODMB complex are listed in Table 4.2. 
4.5.2 STRUCTURE DETERMINATION AND REFINEMENT 
CODMB 
The isomorphous replacement technique was inappropriate smce no published 
coordinates were available for isomorphous structures. The strategy employed in 
attempting to solve the structure by direct meth~ds involved using options available in 
the program SHELXS-86, 1 for example varying the starting reflection subsets, the value 
of Emin and the number of cycles of tangent refinement. Numerous computations were 
performed but none of these yielded a phase set with a combined figure of merit less than 
0.18 and no E-map revealed a sensible molecular fragment. Several attempts to solve the 
structure by Patterson search methods using the program P ATSEE2 were also 
unsuccessful. Due to time constraints, it was necessary to abandon further attempts. 
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Table 4.2 Data-collection and cell data for CODMB 
Molecular formula Cs6H9803s·CIOH1103Cl·5.4H20 
Mr/gmol-1 1643.3 
Crystal system Orthorhombic 
Space group P212121 
z 4 
a (A) 10.78(1) 
b (A) 15.34(1) 
c (A) 49.39(1) 
V(A3) 8167(4) 
De (g cm-3) 1.336 
Crystal dimensions (mm) 0.3x0.4x0.3 
TIK 293(1) 
F(OOO) 3520 
Detector to crystal distance (mm) 50 
Set 1 
Initial settings 4.7 
e CO) 0 
K (o) 180 
(J) (0) 
Number of frames via ~ 320 
~~ scans (0) per image 0.5 




e (0) -9.8 
K (o) -148 
Number of frames via ro 85 
~ro scans CO) per image 0.5 
Exposure time (s) 243 
Reflections collected 7492 
Unique reflections 7477 
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COTMB 
The crystal structure of COTMB was solved by the isomorphous replacement method 
using co-ordinates of non-hydrogen atoms (excluding 0(6), C(7), C(8) and C(9) atoms) 
of the host Trimeb in the isomorphous Trimeb complex of menthol.3 The structure was 
refined by full-matrix least-squares using the program SHELXL-934 with subsequent 
location of the remaining non-hydrogen atoms of the host, guest and the water molecules 
from successive electron density maps. Hydrogen atoms bonded to the carbon atoms of 
the both host and guest were inserted in idealised positions (C-H bond length of 0.98A) 
and their separate common variable temperature factors were allowed to refine freely. 
Since TG analysis indicated 1.4 H20 molecules per CD molecule, the water content was 
modelled based on these data. The 1.4 H20 molecules appeared to be distributed over two 
sites, with site occupancy factors of 0.89 and 0.51. The structure solution appeared to be 
successful as the guest molecule was clearly resolved. The refinement converged to an 
R1-factor of 0.087 based on observed reflections with 1>2cr(I). The maximum and 
minimum residual electron densities were 0. 709 and -0.854 e A-3 respectively. 
74 
DIMEB AND TRIMEB COMPLEXES OF CLOFIBRIC ACID 


















Detector to crystal distance (mm) 
Number of frames via~ 
~~ scans (0 ) per image 
Exposure time ( s) 










































DIMEB AND TRIMEB COMPLEXES OF CLOFIBRIC ACID 
4.5.3 MOLECULAR PACKING AND HOST -GUEST INTERACTION 
The numbering schemes for clofibric acid and the glucose units of Trimeb are shown in 
Figure 4.3. The carboxylic oxygens were distinguished from each other based on the 
magnitudes of their bond lengths. 0(13) represents the carbonyl oxygen atom while 
0(14) is a hydroxyl oxygen atom. The mode of drug inclusion is rather unusual in 
COTMB. The carboxylic group of the guest is buried inside the cavity, instead of the 
chlorophenyl ring, as one might have expected. The insertion occurs on the 0(2), 0(3) 
side of the Trimeb cavity as shown in Figure 4.4. The two oxygen atoms 0(13) and 0(14) 
of the carboxylic group of clofibric acid form hydrogen bonds with the water molecules 
O(W2) and O(W1) respectively. The O(W1) and (OW2) molecules in turn form hydrogen 
bonds with the disordered 0(6G4) atoms ofthe host (see Figure 4.4). The intermolecular 
hydrogen bonds are listed in Table 4.4. The primary (0(6)) side is virtually closed up by 
the C(9) methyl groups giving the interior of the cavity a cup-shaped structure. Figure 4.5 
shows space-filling diagrams which reveal how the guest molecule is buried in the cup-
shaped Trimeb cavity. The chlorophenyl ring of the guest molecule makes a dihedral 
angle of78.9(2)0 with the 0(4) plane ofthe host molecule. The hydrogen bonds between 
water molecules and the guest molecules play a role in stabilising the complex. Complex 
units for COTMB are packed in a head-to-tail fashion in a continuous channel mode 
along the a-axis as shown in Figure 4.6. 
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013 
Figure 4.3 The numbering schemes for clofibric acid (left) and permethylated glucose 
unit (right) 
(a) View into the Trimeb cavity from the primary side 
(b) View perpendicular to the host axis 
Figure 4.4 Stereodiagrams of the COTMB complex 
In the diagrams, A= 0(6G4A) and B = (06G4B), 1 and 2 represent the oxygen O(W1) and 0(W2) atoms 
of the water molecules, 13 represent 0(13), the cabonyl 0 atom and 14 represent 0(14), the hydroxyl 0 
atom (see Table 4.4). 
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Figure 4.5 Space-filling diagrams of the COTMB complex (a) from the 0(6) side of the 
host, (b) from the 0(2),0(3) side ofthe host and (c) the stick representation of guest in 
(b) 
78 
DIMEB AND TR.IMEB COMPLEXES OF CLOFIDRIC ACID 
Table 4.4: Intermolecular hydrogen bonds 










Figure 4.6 Packing diagram for COTMB viewed down the b-axis. For clarity, only three 
columns of the complex molecules are illustrated 
4.5.4 HOST CONFORl\lATION 
The conformation of the Trimeb molecule in COTMB is similar to that occurring in many 
complexes reported in the literature. All methylated glucose residues of the Trimeb 
molecule are in a ~C 1 chair conformation. Four of the C(9) atoms of the methyl glucose 
units show disorder, namely C(9G 1), C(9G2), C(9G4), C(9G7). Generally, the bond 
lengths and bond angles conform to those of other knO\vn cyclodextrin complexes except 
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for the disordered atoms mentioned above. The C( 6)-0( 6) bonds in G4 and G5 have a 
(+)-gauche conformation, while all other C(6)-0(6) bonds are in a (-)-gauche5 
conformation. All important geometric parameters for the Trimeb molecule such as radii 
of the 0(4) heptagon, tilt angles, glycosidic angles, 0(4)···0(4') distances and the 
deviations of the 0( 4) atoms from their least-squares plane are listed in Table 4.5. From 
the tilt angles listed in Table 4.5, it is evident that the Gl, G3, G4, G5 and G7 glucose 
units are tilted in such a way that 0(6)-C(9) groups almost close up the primary side of 
the Trimeb molecule. The shape of the Trimeb molecule is maintained by six 
intramolecular C-H···O hydrogen bonds, namely the C(6Gn)-H···0(5G0 _1) bonds which are 
listed in Table 4.6. 
4.5.5 GUEST CONFORMATION 
Except for the orientation of the carboxylic group, the conformation of the clofibric acid 
molecule in the COTMB complex is similar to that occurring in pure clofibric acid as 
reported by Kennard et al. 6 Table 4.7 shows the interatomic distances and angles about 
the carboxylic chain for complexed and pure drug molecules while the relevant torsion 
angles are shown in Table 4.8. The numbering scheme used for clofibric acid is shown in 
Figure 4.3. A comparison of the C=O bond distances in the complexed and uncomplexed 
clofibric acid showed that the C=O length of the complexed drug is significantly shorter 
(1.17(1)A) than in the uncomplexed drug (1.231(6)A). These results are in good 
agreement with theIR data (section 4.4). 
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Table 4.5 Geometric data for the Trimeb molecule in COTMB 
The glycosidic oxygen angle C4G0-04G0-C1Gn+l (
0
) and the torsion angle index (0 ) 
C( 4G 1 )-0( 4G 1 )-C( 1 G2) 116.9(5) G1 128.7 
C(4G2)-0(4G2)-C(1G3) 118.3(5) G2 135.8 
C( 4G3 )-0( 4G3 )-C( 1 G4) 117.9(5) G3 104.5 
C( 4G4 )-0( 4G4 )-C( 1 G5) 114.8(5) G4 136.7 
C( 4G5)-0( 4G5)-C(1 G6) 118.8(5) G5 142.4 
C( 4G6)-0( 4G6)-C( 1 G 7) 117.4(4) G6 113.5 
C( 4G 7)-0( 4G 7)-C( 1 G 1) 116.4(5) G7 133.1 
Glucose unit Tilt angle Radius of 0( 4G") ... O( 4Gn+l) Deviation 
(0) heptagon (A) (A) 
(A) 
G1 26.7(2) 5.13(1) 4.45(1) -0.537(4) 
G2 -12.9(2) 5.41(1) 4.34(1) 0.157(5) 
G3 9.9(2) 4.94(1) 4.62(1) 0.388(4) 
G4 47.3(2) 5.20(1) 4.31(1) -0.216(4) 
G5 20.5(2) 4.60(1) 4.23(1) -0.489(5) 
G6 -14.8(2) 5.13(1) 4.53(1) 0.457(4) 
G7 42.4(2) 5.10(1) 4.28(1) 0.078(4) 
All parameters are described in section 1.5.2.1 
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Table 4.6 Intramolecular C-H···O hydrogen bonds in COTMB 
Distance (A) Angle(0 ) 
c H 0 Coo•Q C-H H•ooQ C-H .. ·O 
C(6G1) H(6G1A) 0(5G7) 3.19(1) 0.97(1) 2.51(1) 138.1 
C(6G2) H(6G2A) 0(5G1) 3.37(1) 
C(6G3) H(6G3A) 0(5G2) 3.16(1) 0.97(1) 2.55(1) 123.4 
C(6G5) H(6G5A) 0(5G4) 3.22(1) 
C(6G6) H(6G6A) 0(5G5) 3.16(1) 0.97(1) 2.72(1) 127.6 
(-)No hydrogen atoms were attached to the C(6G2) and C(6G5) atoms because they are disordered. 
Table 4. 7 Interatomic distances (A) and angles (0 ) associated with the the carboxylic acid 
Complexed clofibric acid Uncomplexed clofibric acid6 
C(12)-0(13) 1.17(1) 1.231(6) 
C(12)-0(14) 1.30(1) 1.283(6) 
C(9)-C(12)-0(13) 123.4(1) 119.3(2) 
C(9)-C(12)-0(14) 113.6(1) 111.6(4) 
0(13)-C(12)-0(14) 123.0(1) 124.0(5) 
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Table 4.8: Selected torsion angles 
Complexed clofibric acid Uncomplexed clofibric acid 6 
C(4)-C(5)-0(8)-C(9) 








The angles C(4)--C(5)-0(8) and C(6)-C(5)-0(8) whose values are 109.3(7)0 and 128.4(7)0 
respectively show significant deviations from the expected trigonal angle of 120°. Similar 
deviations have also been observed in the crystal structure of pure clofibric acid where 
the corresponding angles were 114.2(2)0 and 124.0(2)0 respectively. 6 Such deviations are 
due to molecular crowding caused by the steric requirement of the bulky isopropionic 
acid side chain. The deviations are somewhat larger in the complexed drug than in pure 
clofibric acid. Such differences can be attributed to the fact that the isopropionic acid side 
chain is more nearly coplanar with the chlorophenyl ring in the complexed clofibric acid 
than in the uncomplexed clofibric acid. 
4.6 X-RAY POWDER DIFFRACTION (XRD) 
The complexes were characterised by XRD as described in Section 2.6. The calculated 
XRD pattern for the COTMB complex was obtained by using a program 
LAZYPUL VERIX7 on a personal computer running in the DOS operating system. The 
XRD patterns for the CODMB complex and the 1:1 physical mixture of clofibric acid 
with Dimeb are shown in Figure 4.7. 
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The XRD pattern for CODMB is distinctive and differs significantly from that of the 1: 1 
physical mixture. This confirms that CODMB is a new phase with its own characteristic 
crystal structure. The experimental and calculated XRD patterns for COTMB are shown 
in Figure 4.8. There are very close matches in the peak positions as well as in the relative 
intensities for the calculated and experimental XRD patterns. This demonstrates that the 
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0+-~~~~~~~~~~~~~~~~~~ 
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Figure 4.8 Experimental and Calculated XRD patterns for COTMB 
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CHAPTER 5: TRIMEB COMPLEX OF CLOFIBRATE 
5.1 INTRODUCTION 
Clofibrate ( ethyl-2-( 4-chlorophenoxy)-2-methylpropionate) (II) is an ester derivative of 
clofibric acid. This compound is poorly water-soluble, bitter tasting and oily. The boiling 
point of clofibrate is 148-150 °C. Like clofibric acid, clofibrate is also an anti-
hyperlipoproteinemic drug and is used for the treatment of some forms of 
hyperlipidaemia. In vivo studies showed that clofibrate is hydrolysed to clofibric acid and 
it is believed that clofibric acid is the active metabolite.' 
Clofibrate is sensitive to photo-oxidation. The photochemical stability of clofibrate and 
its CD complexes were studied by Uekama et al.2 These authors suggested that the 
photodegradation of clofibrate in P- and y-CD is much lower than that of the pure drug, 
indicating prolonged storage time for complexed drugs. Therefore, the fact that 
complexation might reduce the extent of photochemical reaction is advantageous. 
Cyclodextrin complexation of clofibrate also serves as an advantage in that the liquid 
guest compound can be transformed into solid complexes, making them suitable for 
tabletting. Anguiano-Igea et al.3 have characterised the P-CD inclusion complex of 
clofibrate using XRD, DSC and IR spectroscopy. These authors also carried out 
dissolution rate studies which showed that the clofibrate entrapped in the inclusion 
complex dissolved much faster than uncomplexed liquid clofibrate. 
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Recently Anguiano-Igea et al. 4 in a separate publication reported NMR studies of the P-
CD clofibrate inclusion compound, where it was suggested that the host-guest 
interactions in the complex are predominantly hydrophobic in nature occurring between 
the clofibrate phenyl ring and the interior of the P-CD cavity. These NMR data were also 
used to generate a three-dimensional model of the inclusion complex and it was 
suggested that the guest chlorophenyl ring is inserted in the CD cavity from the 
secondary side of the macrocycle while the isopropionate side chain of clofibrate 
protrudes from the primary end of the P-CD molecule. 
5.2 PREPARATION OF COMPLEXES 
The Trimeb complex of clofibrate was prepared by kneading equimolar amounts of 
Trimeb and clofibrate with a minimum amount of ethanol using a mortal and pestle. The 
kneaded complex was then recrystallised from water to yield single crystals which were 
later used for single crystal X-ray analysis. The complex will be referred to as CETMB. 
5.3 THERMAL ANALYSIS 
The TG-DSC traces of CETMB are shown in Figure 5.1. The TG trace shows a 1.1 % 
mass loss in the temperature range 30 to 70 °C, which is equivalent to exactly one water 
molecule per Trimeb molecule. Dehydration is evident as endotherm A in the DSC trace. 
The anhydrous CETMB complex melts at 140 °C, represented by endotherm B on the 
DSC trace. This is similar to the behaviour of the Trimeb complex of ibuprofen reported 
earlier. 5 
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Figure 5.1 TG-DSC trace for CETMB complex 
5.4 SINGLE CRYSTAL ANALYSIS 
5.4.1. DATA-COLLECTION 
X-ray diffraction data were collected on a Nonius Kappa CCD diffractometer using 
graphite-monochromated MoKa radiation generated at 50kV and 30mA. A crystal of 
0.45 x 0.35 x 0.25mm was mounted on a glass fibre. The data were first collected at 293K 
but following refinement of the host molecule, the guest molecule could not be resolved 
from the difference electron density maps. It was then decided to collect the data at lower 
temperature (173K) by cooling the crystal continuously in a stream of nitrogen vapour 
from an Oxford Cryostream. The mounted crystal was inserted into a Lindemann 
capillary. This was necessary in order to minimise exposure to condensation from the 
- .... 
atmosphere. Details of the data-collection strategy are listed in Table 5 .1. 
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5.4.2 STRUCTURE DETERMINATION AND REFINEMENT 
The crystal structure of CETMB was solved by the isomorphous replacement method 
using co-ordinates of the non-hydrogen atoms (excluding 0(6), C(7), C(8) and C(9) 
atoms) of the host Trimeb in the isomorphous Trimeb complex of (S)-naproxen.6 The 
structure was refined by full-matrix least-squares refinement using the SHELXL-93 
program 7 with subsequent location of the remaining non-hydrogen atoms of the host and 
guest molecules from the electron density map. Hydrogen atoms bonded to the carbon 
atoms of both host and guest were inserted in idealised position (C-H bond length of 
0.98A) and their separately assigned common variable isotropic temperature factors were 
allowed to refine freely. All non-hydrogen atoms of the guest molecule were clearly 
resolved and refinement of these atoms proceeded satisfactorily. The guest phenyl ring 
was modelled as a rigid hexagon. Toward the end of the refinement, the expected single 
water molecule was sought in a difference electron density map. The most prominent 
peak had an acceptable electron density of approximately 2 eA-3 and refined successfully 
when assigned a scattering factor of oxygen. However, subsequent inspection of 
geometric parameters showed this peak to be unacceptably close (2.37(1)A) to a carbon 
atom of the guest molecule (C(lO)). The peak was accordingly excluded from the 
refinement. No other prominent peak appeared in the map and it was concluded that the 
single water molecule was probably disordered over more than one crystallographic site. 
Final fractional co-ordinates for all atoms of the CETMB complex are given in Appendix 
A on the appended diskette in ASCII format under the filename CETMB.TEX. 
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Appendix B, also on diskette gives a full listing of observed (F0 ) and calculated (Fe) 
structure factors. These are given under the filename CETMB.SFT. 
5.4.3 HOST-GUEST INTERACTION AND CRYSTAL PACKING 
The numbering scheme of clofibrate is shown in Figure 5.2 and that of the methyl 
glucose moiety is shown in Figure 4.3 (previous chapter). The oxopropionate chain of 
clofibrate is inserted into the Trimeb cavity from the 0(2), 0(3) side as shown in Figure 
5.3. The oxopropionate chain conforms to the shape of the macrocylic cavity by bending 
toward the chlorophenyl ring (see Figure 5.4). 
Figure 5.2 The numbering scheme and conform~tion of the clofibrate molecule in the 
complex. Only the non-hydrogen atoms are illustrated for clarity 
Figure 5.3 Stereodiagram of the complex CETMB: A vic::w into cavit; from the:: 0(2). 0(3 1 side:: 
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Figure 5.4 Stereodiagram of the complex CETMB: a view perpendicular to the host axis 
The chlorophenyl ring makes a dihedral angle of 113° with the least-squares plane 
through the 0( 4) atoms of the host molecule. The host-guest interaction is predominantly 
hydrophobic in nature. There are no intermolecular hydrogen bonds between host and 
guest. These observations are consistent with the mode proposed by Anguiano-Igea et al.4 
based on NMR data of the P-CD complex of clofibrate. However, whereas these authors 
proposed that the chlorophenyl ring residue inserts into the P-CD cavity, the present 
study revealed that with Trimeb as host, the chlorophenyl ring protrudes from the 
secondary side and the side chain preferentially inserts into the cavity. Figure 5.5 shows 
space-filling diagrams for CETMB, which reveal how the guest molecule is buried in the 
cavity. 
The crystal packing arrangement of the CETMB complex is shown in Figure 5.6. The 
host molecules are packed in a head-to-tail packing mode, forming a screw channel 
structure parallel to the b-axis. This packing arrangement is similar to that of the 
isomorphous Trimeb complexes of (S)-naproxen6 and ibuprofen. 8 
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Figure 5.5 Space-filling diagrams ofthe CETMB complex. A view from (a) the 0(6) side 
ofthe host, (b) the 0(2), 0(3) side of the host, and (c) the stick representation ofthe guest 
in (b) 
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Figure 5.6 Packing diagram for the CETMB complex. Selected molecules are included 
for clarity 
5.4.5 CONFORMATION OF THE HOST MOLECULE 
All seven tri-methylated glucose residues of the Trimeb molecule in the CETMB 
complex are in the 4C1 chair conformation. The C(6)-0(6) bonds of the G2, G4 and G7 
glucose units have a (+)-gauche conformation while those of G3, G5 and G6 have a(-)-
gauche conformation. The geometric parameters of the Trimeb molecule are listed in 
Table 5.2. The average distance of the 0(4) atoms from the centre of the macrocycle is 
5.19A. The 0(4) atoms of the host molecule deviate significantly from planarity as 
indicated in Table 5.2. Due to the absence of possible hydrogen bond donor atoms in the 
Trimeb molecule, it does not have the round shape characteristic of the ~-CD molecule. 
This results in large tilt angles between the methyl glucose moieties and the least-squares 
plane through the 0( 4) atoms, which in turn results in a cup-shaped structure for the 
Trimeb molecule. The intramolecular C-H-··0 bonds play a role in partially maintaining 
the conformation of the macrocycle. 
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These are mainly the C(6G0 )-H···0(5G"_1) interactions, which are listed in Table 5.3. 
Table 5.2 Geometric data for the Trimeb molecule in CETMB 
The glycosidic oxygen angle C4G0 -04G0-C1Gn+l (
0) and the torsion angle index (0) 
C(1G 1 )-0(4G2)-C(4G2) 119.1(6) G1 124.4 
C(1 G2)-0( 4G3)-C( 4G3) 117.4(6) G2 139.0 
C( 1 G 3 )-0( 4G4)-C( 4G4) 116.6(7) G3 111.2 
C( 1 G4 )-0( 4G5 )-C( 4G5) 118.4(6) G4 134.8 
C(1 G5)-0( 4G6)-C( 4G6) 118.5(6) G5 124.9 
C(1 G6)-0( 4G7)-C( 4G7) 116.5(6) G6 124.8 
C( 1 G 7)-0( 4G 1 )-C( 4G 1) 116.2(5) G7 143.3 
Glucose unit Tilt angle Radius of 0( 4G0 ) .. -0( 4Gn+l) Deviation 
(0) heptagon (A) (A) (A) 
G1 27.8(2) 5.44(1) 4.45(1) 0.364(5) 
G2 14.7(3) 5.19(1) 4.27(1) 0.199(5) 
G3 -12.0(3) 5.04(1) 4.50(1) -0.596(6) 
G4 44.7(2) 5.29(1) 4.26(1) - -0.115(7) 
G5 36.3(2) 5.20(1) 4.19(1) 0.555(5) 
G6 -19.8(1) 5.15(1) 4.47(1) -0.340(6) 
G7 34.4(2) 4.82(1) 4.84(1) -0.413(6) 
All parameters are defined in section 1.5.2.1 
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Table 5.3 Intramolecular C-H .. ·O hydrogen bonds in CETMB 
Distance (A) Angle(0 ) 
c H 0 C···O C-H Hoo•O C-H .. ·O 
C(6G1) H(6G1A) 0(5G7) 3.22(1) 0.98(1) 2.61(1) 121.3(9) 
C(6G2) H(6G2B) 0(5G1) 3.39(1) 0.97(1) 2.54(1) 147.7(9) 
C(1G3) H(1G3) 0(3G4) 3.11(1) 0.97(1} 2.46(1) 123.8(8) 
C(6G3) H(6G3A) 0(5G2) 3.21(1) 0.97(1) 2.51(1) 128.9(9) 
C(1G5) H(1G5B) 0(6G5) 3.25(1) 0.98(1) 2.51(1) 132.3(8) 
C(6G5) H(6G5A) 0(5G4) 3.14(1) 0.98(1) 2.44(1) 129.2(1) 
C(6G6) H(6G6A) 0(5G5) 3.17(1) 0.97(1) 2.65(1) 134.2(8) 
5.4.5. CONFORMATION OF THE GUEST MOLECULE 
The conformation of clofibrate in CETMB is somewhat similar to that of complexed and 
uncomplexed clofibric acid (see section 4.5.5). Clofibrate is liquid at room temperature 
and no crystal structure of low temperature forms have been published.9 The crystal 
structure of CETMB has therefore enabled elucidation of the structure of clofibrate. The 
numbering scheme of clofibrate is given in Figure 5.2. The conformation is defined by 
the torsion angles listed in Table 5.4. The C(4)-C(5)-0(8) and C(6)-C(5)-0(8) angles are 
125.8(8) and 113.8(8)0 respectively. These deviate significantly from the expected 
trigonal angle as in clofibric acid (see Section 4.5.5). Overall, most bond angles and 
distances are in good agreement with those observed in other related molecules.9 
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Table 5.4 Torsion angles e) for the clofibrate molecule 
C(6)-C(5)-0(8)-C(9) -165(2) 
C(5)-0(8)-C(9)-C(1 0) 177(1) 
C(5)-0(8)-C(9)-C(11) 72(2) 
C(5)-0(8)-C(9)-C(12) -60(2) 
0(8)-C(9)-C( 12 )-0( 13) 147(2) 
0( 8 )-C( 9 )-C( 12 )-0( 14) -29(2) 
C(9)-C( 12)-0(14)-C( 15) -171(2) 




5.5 X-RAY POWDER DIFFRACTION 
The CETMB complex was characterised by XRD as described in Section 2.6. The 
theoretical XRD pattern was calculated using the program LAZYPUL VERIX10 on a 
personal computer running under the DOS operating system. The experimental and 
calculated XRD patterns for CETMB are shown in Figure 5.7. Comparison of the 
calculated and experimental powder XRD patterns for CETMB shows that both peak 
positions and relative intensities are in good agreement. This demonstrates that the 
sample used for the powder XRD analysis is of high purity. 
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Figure 5.7 Calculated and experimental XRD patterns for CETMB 
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CHAPTER 6: CYCLODEXTRIN INCLUSION OF BENZODIAZEPINES 
6.1 INTRODUCTION 
There is an increasing interest in studying CD inclusion complexes of drugs of the 
benzodiazepine farnily.l-4 These drugs possess a range of biological activities, most of 
which involve interactions with the nervous system receptors. Two benzodiazepine drug 
molecules were chosen to be studied in this project as possible guests for CD inclusion. 
They are alprazolam, 8-chloro-1-methyl-6-phenyl-4H-[1 ,2,4]triazolo[ 4,3-a][l ,4] 
benzodiazepine (III), which is an anxiolytic drug, and midazolam, 8-chloro-6-(2-





~ \ ~ \ 
~N ~N 
Cl Cl F 
III IV 
Most of the benzodiazepine drugs have a very low aqueous solubility. 1 A number of 
chemical investigations have been carried out on the inclusion complexes of 
benzodiazepines with the aim of increasing bioavailability and changing the spectrum of 
pharmaceutical activity. Some of the benzodiazepines studied are chlordiazepoxide, 1 
gidazepam,1 cinazepam, 1 and nitrazepam4 with P-CD and y-CD using IR spectroscopy, 
101 
CYCLODEXTRIN INCLUSION OF BENZODIAZEPINES 
thermal analysis and X-ray diffractometry. Studies in aqueous solution which were 
carried out by Uekama et al. 2 and Abdel-Rahman et al.3 revealed the magnitude of host-
guest interaction between several benzodiazepines and a-, p-, and y-CD. These authors 
independently found that the stability constant of the CD complexes with 
benzodiazepines generally increase in the order a- < y- < P-CD, suggesting that in 
aqueous media the size of the cavity of P-CD most favourably accommodates the 
benzodiazepine molecules. 
One- and two-dimensional 1H-NMR studies of the inclusion compounds of gidazepam 
and cinazepam with P-CD have revealed that the phenyl ring of gidazepam and the o-
chlorophenyl ring of cinazepam are inserted into the P-CD hydrophobic cavity. 1 Based on 
the NMR data for gidazepam 1 and cinazepam, 1 it is expected that the formation of CD 
inclusion compounds of alprazolam could involve the insertion of the phenyl ring into the 
CD cavity while the fluorophenyl ring of midazolam could be inserted in the cavity. 
Nevertheless, this can only be ascertained by elucidating the structures of such 
complexes. 
In this chapter we report the results of solubility studies of alprazolam and midazolam in 
P-CD, Rameb (randomly methylated P-CD) and 2-hydroxypropyl P-CD (2-HPP-CD) 
solutions, attempts to prepare solid complexes and the crystal structure of midazolam 
sesquihydrate. 
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6.2 SOLUBILITY STUDIES 
6.2.1 METHODOLOGY 
The phase solubility studies for midazolam were carried out at pH 7, pH 5.8 and pH 4 
using RAMEB and 2-HPP-CD as solubilising agents. This was necessary to assess the 
effect of pH on the solubility enhancement capacity of CDs on midazolam. Studies for 
alprazolam were carried out in de-ionised water using Rameb, 2-HPP-CD and P-CD as 
solubilising agents. RAMEB and 2-HPP-CD stock solutions of various concentrations in 
the range 15 to 200 mg ml-1 were prepared. Stock solutions of P-CD were in the range 2 
to 18 mg ml-1• Aliquots (5 ml) of the prepared CD solutions were individually pipetted 
into 25 ml stoppered flasks. Excess amounts of drugs were added to fixed volumes (5 ml) 
of solubility medium containing various concentrations of cyclodextrin solutions. The 
tightly stoppered flasks were then shaken using a Shake-0-Mat Labotec shaker at 220 
rpm at room temperature for 48 h. The solutions were filtered through a 0.22 Jlm filter 
and the drug concentrations in the filtrates were determined by UV spectrophotometry on 
a Philips PU8700 UV/vis spectrophotometer. 
6.2.2 PHASE DIAGRAMS AND STABILITY CONSTANTS FOR MIDAZOLAM 
The results of the phase solubility studies for midazolam in RAMEB and HPBCD 
solution are shown graphically in Figures 6.1 (pH 4), 6.2 (pH 5.8) and 6.3 (pH 7) . The 
Rameb-midazolam curves show an~ type behaviour at all pH values, while 2-HPP-CD-
midazolam curves show~ behaviour at pH 7 and AL behaviour at pH 5.8 and 4. 
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At any given pH, RAMEB showed a higher solubilising effect on midazolam compared 
to 2-HPP-CD. 
The stability constants for the AL sytems were calculated by using equation 6.1. 5 
K = m 
II [so ] (1 - m) 
and that of the Ar systems by: 










where m = the slope of the phase solubility curve, [So] = concentration of drug in pure 
buffer solution, [ S1] = the concentration of the drug in different CD solutions, [Lr] = CD 
concentration, K 11 and K 12 are the stability constants. 
The graph of [S,]- [So] vs. [L,] yields a y-intercept which is equal to K
11 
[So] while the 
[L,] 
slope is equal to K 11 K 12 [ S oJ. Table 6.1 shows solubility data for midazolam in both 
RAMEB and 2-HPP-CD. 
Table 6.1: Solubility data for midazolam in RAMEB and 2-HPP-CD 
Host pH Enhancement Diagram type Stability constant 
factor a [M-1] 
RAMEB pH4.0 23 Ar K11 26.7 K 12 0.03 
2-HPP-CD pH4.0 7 AL K11 49.7 
RAMEB pH 5.8 200 Ar 
2-HPP-CD pH 5.8 47 AL K11 356.9 K 12 0.01 
RAMEB pH 7.0 490 A, 
2-HPP-CD pH7.0 96 A, K11 332.1 K 12 0.01 
• solubility of drug in 20g/100ml CD solution divided by solubility in buffer solution only 
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The solubilising power of Rameb at higher Rameb concentration is barely affected by pH 
As a result the solubility enhancement factor of midazolam increases with increase in pH 
40 
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Figure 6. 1 Phase solubility diagrams for midazolam in Rameb and 2-HP~-CD at pH 4 
CD concentration [mg/ml] 
Figure 6.2 Phase solubility diagrams for midazolam in Rameb and 2-HP~-CD at pH 5.8 
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Figure 6.3 Phase solubility diagrams for midazolam in Rameb and 2-HPJ3-CD at pH 7 
These diagrams (Figures 6.1 to 6.3) indicate that the complexes formed are highly soluble 
in water and suggest that attempted preparation of Rameb and 2-HPJ3-CD complexes of 
midazolam at pH 4, 5.6 and 7 by co-precipitation is unlikely to yield solid complexes. 
6.2.3 PHASE DIAGRAMS AND STABILITY CONSTANTS FOR ALPRAZOLAM 
The phase solubility diagrams for Rameb- and 2-HPJ3-CD-alprazolam are shown in Figure 
6.4 and for the J3-CD-alprazolam system in Figure 6.5. Both Rameb-alprazolam and 2-
HPJ3-CD-alprazolam curves show an AL type behaviour in de-ionised water, while the J3-
CD-alprazolam curve resembles a B8 type curve. Table 6.2 shows solubility data as well as 
stability constants for Alprazolam in J3-CD, Rameb and 2-HPJ3-CD. Evidently there is a 
stronger host-guest interaction between Rameb and alprazolam than between 2-HPJ3-CD 
and alprazolam as reflected in Table 6.2 below. 
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a solubility of drug in 20g/1 OOml Rameb or 2-HPI3-CD solution divided by solubility in 











~ 1 a. 
ct 
0 50 100 150 200 
CD concentration [mg/ml] 
Figure 6.4 Phase solubility diagrams for alprazolam in Rameb and 2-HPI3-CD solutions 
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Figure 6.5 Phase solubility diagram for alprazolam in the J3-CD solution 
6.3 CD COMPLEXES OF BENZODIAZEPINES 
In this study, preparations of J3-CD, y-CD and Trimeb complexes of alprazolam as well 
as midazolam by the following co-precipitation methods were attempted: 
• Method A: drugs were added to a CD solution (1: 1 molar ratio drug : CD) and the 
mixture was stirred for 36 h at 65 °C. 
• Method B: drugs were pre-dissolved in a minimum amount of hot ethanol (at 65 °C). 
The drug-ethanol solution was then added to a CD solution and was stirred for 36 h at 
65 °C. 
• Method C: equimolar amounts of drugs were added to hot CD solutions, followed by 
the addition of 0.2 M HCl dropwise until the dfll;g dissolved completely. The solution 
was stirred for 24 h followed by dropwise addition of0.2M NaOH. 
All solutions were filtered with a 0.45f..1m filter with the aim of growing single crystals. 
During the course of the attempted preparation of CD complexes, crystals formed by 
methods A and B were analysed by UV, DSC and TG, but were found to be CD hydrates. 
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The attempted preparation of the P-CD complex of midazolam by method C produced 
crystals of the hydrates of midazolam and P-CD. The midazolam hydrate crystallised out 
much faster (within 6 hours) than P-CD hydrate. The midazolam hydrate was 
characterised by thermal analytical methods and the results are discussed in section 6.4. 
Since no crystal structure of midazolam has been reported, 6 it was decided to carry out 
complete single crystal X-ray analysis. Knowledge of the conformational features of 
midazolam was also considered to be useful for future studies aimed at modelling the 
inclusion of midazolam in cyclodextrins. 
6.4 THERMAL ANALYSIS OF MIDAZOLAM SESQUIHYDRATE 
Figure 6.6 shows DSC and TG traces for the hydrate of midazolam. The stoichiometry 
was calculated from mass loss observed on the TG trace. The TG showed 7.6% mass loss 
from 30 to 135.9 °C, which is equivalent to 1.5 H20 molecules per midazolam molecule. 
The DSC shows an endotherm A ( onset temperature Ton = 92. 7°C) which corresponds to 
the desorption of water, and exotherm B (Ton= 115.3 °C) corresponding to desorption of 
water and possibly a structural phase change. Endotherm C (Ton= 163.2 °C) corresponds 
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Figure 6.6 TG-DSC traces for midazolam sesquihydrate 
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6.5 CRYSTAL STRUCTURE OF MIDAZOLAM SESQUIHYDRATE 
6.5.1 X-RAY PHOTOGRAPHY AND DATA-COLLECTION 
Preliminary X-ray photography revealed Laue symmetry 2/m indicating that the 
compound crystallises in the monoclinic system. Conditions for observed reflections from 
precession photographs were hkl h+k = 2n, h0ll=2n and OkO (k=2n). These conditions 
indicate space groups Cc (No. 9) or C2/c (No. 15) which are non-centric and centric 
respectively. Intensity statistics yielded a value l£2-11 of0.774 clearly favouring the non-
centric space group. With Z = 8, this requires the asymmetric unit to contain two 
midazolam molecules and three water molecules. 
Details of the data-collection strategy are given in Table 6.3. Data were collected in two 
sets. The first set of data was collected about 4> at 1.0° scan per image in the range -222 to 
-40° while the second set was collected at 1.0° scan per image about ro in the range 137.7 
to 100.7°. 
6.5.2. STRUCTURE DETERMINATION AND REFINEMENT 
The crystal structure of midazolam was solved by direct methods with program 
SHELXS-867 and refined by full-matrix least-squares with SHELXL-93.8 In the final 
refinement all non-hydrogen atoms were treated anisotropically. All H atoms of 
midazolam were added in idealised positions and were assigned a common isotropic 
temperature factor. 
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Hydrogen atoms of the water molecules could not be located unambiguously in the 
difference electron density maps and are ·omitted in the final model. Unit cell parameters 
and refinement details are listed in Table 6.3. The final R-value converged to 0.075, 
which was satisfactory. Attempts to solve the structure in the space group C2/c were 
unsuccessful, thus further vindicating Cc as the correct choice. The final fractional co-
ordinates for all atoms except hydrogen atoms of the water molecules are given in 
Appendix A on the appended diskette in ASCII format under file name MIDAZ.TEX. 
The observed {F0 ) and calculated (Fe) structure factors are given in Appendix B, also on 
the appended diskette under file name MIDAZ.SFT. 
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6.5.3 CRYSTAL PACKING OF MIDAZOLAM SESQUIHYDRATE 
Two midazolam molecules are in the asymmetric unit and are labelled as molecules A 
and B. The numbering scheme and structure ofmidazolam are shown in Figure 6.7. There 
are three water molecules present for every two midazolam molecules in the hydrate. One 
of the water molecules (atom 0(1)) forms hydrogen bonds with the N(8A) and N(8B) 
atoms which are nitrogen atoms of molecule A and B. The other two water molecules are 
hydrogen bonded to atoms N(12) of the midazolam molecules i.e. the relevant contacts 
are 0(2) .. ·N(12B) and 0(3) .. ·N(l2A). Atoms 0(2) and 0(3) are also hydrogen bonded to 
each other. This results in a complex intermolecular linkage between the two midazolam 
molecules in the asymmetric unit as shown in Figure 6.8. The hydrogen bond data are 
listed in Table 6.4. The packing diagram for midazolam sesquihydrate is shown in Figure 
6.9. Midazolam molecules are packed in layers, forming interstitial channels which are 
occupied by water molecules. It is evident from Figure 6.8 that the asymmetric unit 
shown has C2 pseudosymmetry. The molecular packing results in pseudo-C2 axes 
running parallel to the crystal a-axis, which is evident in Fig 6.9. 
Figure 6.7 Structure and numbering scheme for the midazolam molecule. 
The two independent drug molecules in the asymmetric unit have suffixes A and B added to their labels 
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Figure 6.8 Two midazolam molecules in the asymmetric unit, linked via hydrogen 
bonding through water molecules 
Figure 6.9 Stereopacking diagram for midazolam ~esquihydrate 
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6.5.4 CONFORMATION OF MIDAZOLAM 
Bond lengths and angles are in the expected ranges and compare favourably with those in 
other benzodiazepine molecules.9-12 Selected bond lengths, bond angles, and torsion 
angles are listed in Table 6.5. 
The seven-membered ring adopts a cycloheptatriene-like boat conformation, which is 
common to this class of compounds.9 The 'boat" can be described in terms of angles 
between the least-squares plane through the N(6), C(lO), N(12) and C(l3) atoms and the 
'bow' and 'stem' planes consisting ofthe three atoms C(lO), C(ll), N(12) and the set of 
four atoms N(6), C(5), C(l4), C(13) respectively. The 'bow' and 'stem' angles for 
midazolam are 56.2(4) and 36.6(3)0 in molecule A, and 56.5(4) and 36.6(4)0 in molecule 
B. These values compare favourably with 56.5(7) and 35.5(3)0 in 8-chloro-1-
[(dimethylamino)methyl]-6-phenyl-4H-imidazo [1,2-a][1,4]benzodiazepine11 and 55.8(6) 
and 36.2(6)0 in 1-methyl-6-phenyl-8-(trifluoromethyl)-4H-1,2,4-triazolo[ 4,3-a][l ,4] 
benzodiazepine. 12 The close correspondence between the geometrical parameters for the 
crystallographically independent molecules A and B (Table 6.5) suggests a fairly rigid 
conformation for the midazolam molecule. This merits consideration in further studies of 
modelling ofCD-inclusion ofthis drug. 
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Table 6.5 Selected bond distances (A), bond angles(0 ) and torsion angles (0 ) 
A B 
C(5)-N(6) 1.41(1) 1.43(1) 
C(5)-C(14) 1.41(1) 1.40(1) 
N(6)-C(7) 1.38(1) 1.37(1) 
N(6)-C(10) 1.41(1) 1.40(1) 
C(7)-N(8) 1.31(1) 1.30(1) 
N(8)-C(9) 1.38(1) 1.40(1) 
C(9)-C(10) 1.36(1) 1.34(1) 
C(10)-C(11) 1.47(1) 1.48(1) 
C(11)-N(12) 1.47(1) 1.46(1) 
N(12)-C(13) 1.28(1) 1.29(1) 
C(13)-C(14) 1.49(1) 1.51(1) 
N(6)-C(5)-C(14) 120.5(5) 120.8(5) 
C(5)-N(6)-C(10) 120.2(5) 120.9(5) 
N(6)-C(10)-C(11) 120.6(5) 119.7(6) 
C(10)-C(11)-N(12) 108.8(6) 109.4(6) 
C(11)-N(12)-C(13) 116.9(5) 118.0(5) 
N(12)-C(13)-C(14) 126.1(5) 124.3(5) 
C(5)-N(l4)-C(13) 122.9(5) 123.4(5) 
N(6)-C(5)-C(14)-C(13) 2.4(8) 3.1(8) 
C(5)-N(6)-C(10)-C(11) 43.9(8) 42.5(8) 
C( 14 )-C( 5)-N( 6)-C( 1 0) -8.9(9) -6.6(9) 
N(6)-C(10)-C(11)-N(12) -65.8(7) -65.3(7) 
C(10)-C(11)-N(12)-C(13) 70.5(7) 69.8(7) 
C(11)-N(l2)-C(13)-C(14) -0.4(9) 1.2(8) 
N( 12)-C( 13 )-C( 14 )-C( 5) -45.7(8) -46.4(8) 
N (12 )-C( 13 )-C( 14 )-C( 15) 137.6(5) 136.1(1) 
N(12)-C(13)-C(16)-C(17) -45.9(8) -47.1(6) 
N(12)-C(13)-C(16)-C(21) 134.9(6) 133.6(1) 
C( 14 )-C( 13 )-C( 16)-C( 17) 131.0(6) 129.1(6) 
C( 14 )-C( 13 )-C( 16)-C(21) -48.3(8) -50.2(8) 
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CHAPTER 7: CONCLUSION 
7.1 CONCLUSION 
CONCLUSION 
In this study the following five new cyclodextrin inclusion complexes were prepared 
and characterized by TG, DSC, UV, IR spectroscopy, XRD and single crystal X-ray 
analysis: 
Complex Molecular formula 
CO BCD C42H7o03s·CIOHI1 03Cl·8.4H20 
COGCD C4sHso04o·CIOHI1 03Cl·15.5H20 
CODMB Cs6H9203s·C10HII 03Cl·5.4H20 
COTMB C63HII203s·CIOHII03Cl·1.4H20 
CETMB C63HI1203s·C12His03Cl·H20 
The first four complexes are P-CD, y-CD, Dimeb and Trimeb complexes of clofibric 
acid and the last one (CETMB) is a Trimeb complex of clofibrate. The preparations of 
CD complexes of clofibric acid and clofibrate were relatively straightforward. 
Techniques used in this study proved to be useful in confirming complex formation as 
well as elucidation of their structures. Thermal analysis was used more frequently and 
served as a principal tool to distinguish complexes from physical mixtures. Infrared 
spectra for COBCD, COGCD, CODMB and COTMB showed that the carbonyl 
stretching frequency of the complexed clofibric acid is significantly shifted to higher 
frequency relative to its value in the uncomplexed drug. This indicates that the C=O 
bond is strengthened by complex formation and that this functional group engages in 
new hydrogen bonds in the complexes. 
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The crystal structure analysis for the COBCD and COGCD complexes revealed that 
the included guest molecules are disordered. Such disorders are due to the linearity of 
the channel in COBCD, while the four-fold crystallographic symmetry causes 
disorder of the guest in COGCD. The packing mode of COBCD is similar to that of 
other P-CD complexes which crystallize in the space group C2.1-3 COGCD 
crystallizes in the space group P4212, which is the common space group for y-CD 
complexes known thus far. 4-5 
Studies on the kinetics of dehydration of COBCD, COGCD and their corresponding 
host hydrates are reported in section 3. 7. The magnitude of the activation energy (Ea) 
appeared to be related to the packing modes and the location of the water molecules in 
the crystals. The complexes (COBCD and COGCD) whose molecules are packed in 
channels, lose water more readily than the native cyclodextrin hydrates (P-
CD·l2.5H20 and y-CD·l5.5H20) which crystallise in 'cage' packing arrangements. 
The crystal structure of CODMB could not be solved by either direct or Patterson 
search methods using data collected as described in 4.5.1. It is therefore highly 
recommended that data-collection for this compound be carried out at lower 
temperature to improve data resolution, as this is the probable reason for the problems 
encountered. 
In both the COTMB and CETMB complexes, the guest molecules insert from the 
0(2), 0(3) side of the Trimeb molecule. The aliphatic chain is immersed deep in the 
cavity while the chlorophenyl ring protrudes from the secondary side. This mode of 
inclusion differs from that of native CDs where the guest aromatic ring is often 
inserted into the cavity. In the COTMB complex, water molecules are hydrogen 
bonded to the guest molecule which indeed stabilise the complex. 
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The elucidation of the structure of the CETMB complex is also important in that it 
represents the first X-ray structure determination of clofibrate, revealing one of its 
conformations. 
Preliminary phase solubility studies were carried out on alprazolam and midazolam in 
Rameb and 2-HPj}-CD and revealed a significant solubility enhancement for the two 
species. Attempted preparation of solid cyclodextrin complexes of alprazolam and 
midazolam proved to be unsuccessful using various co-precipitaion methods 
including pH adjustment. This is expected to be the case, considering the fact that 
phase solubility diagrams showed a tendency toward A type behaviour. During the 
course of the preparation of CD complexes of midazolam using pH adjustment 
methods, the host and guest tend to crystallise out separately. Midazolam crystallised 
out as a sesquihydrate whose crystal structure was solved. The structure solution 
revealed that two midazolam molecules form an asymmetric unit linked by three 
water molecules through hydrogen bonds. This suggests that midazolam prefers to 
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Supplementary material for structures of all compounds appear on disks in Appendices A 
and B. 
APPENDIX A 
Appendix A contains 
• atomic co-ordinates and equivalent isotropic displacement parameters 
• bond lengths and angles 
• anisotropic displacement parameters 
• hydrogen atom co-ordinates 
• torsion angles. 
Files containing these data for the complexes are named using the abbreviation for the 
complexes with the extension "TEX" e.g. COBCD.TEX contains the above mentioned 
data for the CODMB complex. Data for midazolam sesquihydrate are stored in 
MIDAZ.TEX. 
APPENDIXB 
This contains tables of observed (F 0 ) and calculated (F c) structure factors. Files containing 
structure factor tables for the complexes are named using the abbreviation for the 
complexes used in the text with extension "SFT", e.g. COBCD.SFT contains the structure 
factor tables for the CODMB complex. The structure factor tables for midazolam 
sesquihydrate are given in MIDAZ.SFT. 
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All files are text files and can be viewed in an editor under any of the following operating 
systems: 
APPLE MAC 
DOS 
Linux 
OS/2 
UNIX 
VMS 
WINDOWS 3.1 
WINDOWS 95 
WINDOWS 97. 
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